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Abstract
Electronic biosensors utilizing micron-scale interdigitate electrodes (IDEs) in an 
SD card format have been developed with the objective of fast, sensitive 
detection of ovarian cancer biomarkers CA-125, CEA, and He4. The signal 
generated by the biosensors is a result of electrochemical impedance 
spectroscopy (EIS), a technique which probes changes that occur in the 
biosensorʼs electrical properties when the biosensor has detected one of the 
target biomarkers. A label-free biosensor has been developed to detect CA-125 
in spiked buffer at concentrations between 10 and 80units/mL. A similar label-free 
biosensor was developed to detect CEA at concentrations between 10μg/mL and 
10mg/mL. A biosensor employing a protein-enzyme conjugated label was 
developed to detect He4 at concentrations ranging from 1.56 to 100ng/mL in 
spiked buffer. All concentration ranges of CA-125, CEA, and He4 detected by the 
biosensors include the serum concentration currently used for clinical diagnosis 
of ovarian cancer. Efforts to improve the signals generated by the biosensors 
included altering the dimensions and composition of the IDEs used in the initial 
biosensors through software-created models. Modeled alterations included the 
size of the electrodes, the shape of the electrodes, and the incorporation of 
nanomaterials into the IDEs. An ideal geometry for the IDEs was developed 
through the models and IDEs with those dimensions were fabricated and tested 
against the IDEs used in the biosensors initially with the model-developed 
geometry improving the signal generated by the biosensor. Another attempt to 
i
improve the biosensorʼs signal was to generate a single strand of DNA (ssDNA) 
that would bind to CA-125, called an aptamer, that could be easily incorporated 
into the sensing layer on the IDEs. Through a multistep selection process nine 
different aptamers that exhibited binding to CA-125 were identified.
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Chapter 1:
Introduction to ovarian cancer, electrical biosensors, aptamers, and 
molecular biology techniques
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1.1Ovarian cancer. Ovarian cancer is the fifth-leading cause of cancer death in 
women [1]. Due to its nonspecific symptoms [2] and lack of an adequate physical 
exam, over 75 percent of cases are diagnosed in the late stages when the 
disease has metastasized beyond the primary site, leading to a five year survival 
rate of less than 30 percent [3]. By comparison, patients diagnosed in the early 
stages have a 90 percent survival rate over the same period [3].
! An ovarian cancer diagnosis results in the classification of the disease into 
stage I, II, III, or IV, with the lower numbered stages being the earliest stages with 
the highest survival rates. In stages III and IV, the cancer has metastasized 
beyond the primary site. Unfortunately, a majority of diagnoses occur in these 
late stages when the survival rate is below 30% [3]. There are three types of 
ovarian cancer: epithelial (90% of cases), germ cell carcinoma (5% of cases), 
and stromal carcinoma (5% of cases).
! CA-125 and CEA are two biomarkers indicated in a number of cancers, 
including ovarian cancer [4,5]. Currently, CA-125 and CEA are used to determine 
the effectiveness of post-surgical treatment for ovarian cancer and colon cancer, 
respectively, and to monitor for disease recurrence [6]. The normal range for 
CA-125 in serum is less than 35 units/mL (U/mL). In healthy patients, CEA will 
not be present in serum at a greater concentration than 10 ng/mL. While neither 
of these markers are suitable for early detection of ovarian cancer on their own, 
an elevated presence of both would appear to make early diagnosis of ovarian 
cancer more feasible.
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! CA-125 is still a poorly understood protein. Despite being discovered in 
1981, [7] its structure and function remain largely a mystery. It was only 
successfully cloned in 2001 [8] despite the ability of research groups and 
biological reagent suppliers to produce the antibodies to it for some time. It is a 
very large transmembrane protein weighing between 200 and 2000 kDa with 
moieties that can separate from the larger protein. It is composed of a short 
cytoplasmic tail, a transmembrane domain, and a very large glycosylated 
extracellular domain all of which are poorly characterized. 
! The structure of CEA is better understood. It was discovered in 1965 [9]. 
With a molecular weight of about 200 kDa it is, like CA-125, a heavily 
glycosylated protein with about 50% of its weight being composed of 
carbohydrate. It includes a small transmembrane domain and a large 
extracellular domain where the glycosylation is located.
! Another promising biomarker is He4.  It was discovered in 2003 and has 
been linked to the occurrence of ovarian cancer [10]. It is currently gaining 
ground in being utilized for ovarian cancer detection. It is found to be elevated in 
most patients at the early stage of the disease and it is indicative if the disease 
has spread beyond the primary site [10]. It is still too early to determine 
experimentally what the required range for detection should be. For the time 
being, populations of healthy and diseased women are monitored to determine 
what constitutes an elevated level of He4. The only assay currently on the market 
to detect He4 in serum samples is available from Fujirebio Diagnostics. 
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According to their studies outlined in the product insert, 94.4% of healthy women 
had an He4 concentration of below 150 pM in serum [11] but there have been 
other estimates as high as 500 pM. Their studies included healthy women, 
women with benign gynecological disease, and women with various types of 
cancer including ovarian, endometrial, and gastrointestinal.
! The structure of He4 is fairly well known. It weighs 13 kDa but in its usual 
glycosylated state it weighs between 20-25 kDa [12]. Thus it is a much smaller 
protein than CA-125 and CEA. He4 is part of a family of whey acidic four-
disulfide core (WFDC) proteins. Proteins classified as WFDC proteins are 
characterized by about 50 amino acid residues including eight conserved 
cysteine residues that form four disulfide bridges [13]. He4 is composed of one 
peptide and two of these WFDC regions [12].
1.2 Biosensor Overview. A survey of the literature shows that considerable 
effort is being directed towards developing biosensors that can overcome the 
limitation of the conventional bioassays currently in use to detect biological 
targets. These sensors target analytes including enzymes, cells, and antibodies 
or antigens. 
! Traditional bioassays are costly, time-consuming, and require specialized 
technicians and equipment to read them. A viable biosensor has to be quick, 
cheap, and portable. Whereas conventional assays are carried out with multiple 
step processes, typically consisting of several binding and washing steps, and an 
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additional reading requirement, electronic biosensors incorporate the sensing 
element and the signal reader together on one device. The detection layer is 
developed on the transducer and when a recognition event occurs between the 
detection layer and the target, the environment around the transducer is altered, 
allowing a measurement [14].
! The idea behind biosensors was developed in 1965 by Leland C. Clark, 
Jr., when he published a paper on an oxygen electrode he had developed [15]. 
His work on sensors to detect glucose relied on an enzymatic relationship 
between glucose and glucose oxidase [16]. His work on glucose detection 
resulted in the first commercially available biosensor in 1975. Glucose detection 
is a prime example of the need for biosensors. For people with diabetes, 
continuous testing of the level of glucose in their blood is required. A biosensor 
fits this need perfectly. It is patient friendly, rapid, and accurate. As long as it is 
provided with a constant stream of glucose oxidase, it is able to make 
measurements of glucose in biological samples like blood [14].
 ! Environmental monitoring will benefit from the development of biosensors 
as well. Water sources can be checked for contaminants and air quality can be 
examined for pollutants. Food freshness and contamination can also be 
monitored with biosensors. Better detection of target molecules in both of these 
fields would lead to better safety and health for the population.
5
! Biosensors are typically broken down into one of four types: 
electrochemical, optical, mass, and thermal. All rely on different techniques to 
record the binding between the target and the sensing layer on the transducer.
! Electrochemical biosensors are the largest class of biosensors [14]. They 
involve some kind of electron transfer reaction under certain physical constraints. 
Examples are electrochemical impedance spectroscopy (EIS), cyclic voltammetry 
[17,18], and potential step chronoamperometry [19], and many more. In these 
sensors the transducer is generally an electrode or a system of electrodes. The 
biosensors developed in the research described in the following chapters fall into 
this category. There are several other types of biosensors that are summarized 
below. 
• Optical biosensors utilize a fiber optic system as a transducer. They are divided 
into two categories: intrinsic, where the optical fiber undergoes direct interaction 
with the target, and extrinsic, where the optical fiber is used to translate the 
signal generated at the binding event into light [20]. The most well known 
example of an optical biosensor is surface plasmon resonance (SPR) [21].
• Mass biosensors rely on a piezoelectric frequency damping on the transducer's 
surface to convert the increase in mass at the detection layer, which comes 
about from the layer's binding with the target, into an informative signal [22-25]. 
A variation of this measurement of the change in micro –or nano-scale 
cantilever (MEMS and NEMS) vibration frequency.   
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• Temperature-based biosensors exploit exothermic and endothermic reactions 
to generate a signal. In this case, a temperature sensor is used as a 
transducer.
• Many biosensors rely on the use of a label, or a molecule attached to the 
target, to either amplify or translate the signal provided by the transducer. 
Common choices for labels are enzymes, fluorescent molecules, and magnetic 
beads. 
! Techniques employing labels are non-ideal for a number of reasons 
including higher cost and extra processing steps. They can also alter the 
conformation of the molecule they are attached to, changing the binding ability, 
specificity, and kinematics of the system. While most of the sensors described in 
the following chapters rely on label-free detection there are a couple of 
exceptions.
! Biosensors have found applications in a number of fields. The medical 
field stands to gain the most from the development of specialized biosensors. 
Ideally, a biosensor for any disease could be developed as long as the antigens 
and antibodies specific to it can be identified or a complimentary capture 
mechanism for the biomarker in question can be identified. Biosensors would 
also allow for disease detection in a point-of-care situation, benefiting patient 
care. Making them further ideal for disease detection, biosensors have the 
capacity to be multiplexed, allowing the device the ability to detect more than one 
disease marker at a time. This is a helpful feature as most diseases produce 
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more than one protein marker. This multiplexing feature would in turn allow for 
highly specific disease detection so that chance of misdiagnosis is reduced.
!
1.3 Electrochemical Impedance Spectroscopy (EIS).  In biosensors, binding of 
molecules at specific sites will result in the modification of the sensor's 
properties. More specifically, the formation of any kind of layer on the transducer 
of the biosensor, generally an electrode in EIS, affects the device's electrical 
characteristics. Additionally, any binding between the bioactive layer and its 
target causes the capacitance and resistance of the system to be altered.
! EIS is an effective tool for investigating the electrochemical characteristics 
of modified transducers [26,27]. The impedance measurement is based on 
measuring the nonlinear response of the circuit elements to the changing input 
AC signal frequency. The impedance is measured with an impedance analyzer 
using the frequency response of the device. It can be expressed as the ratio of 
the system voltage phasor to the current phasor. Using phasors allows for 
incorporation of the phase angle between the current and voltage at different 
frequencies due to the nonlinear response.
! To obtain EIS data, a small AC voltage, up to a several hundred mV, and a 
frequency range from tens of Hz to several MHz is applied to the system and 
used to generate the signal. The impedance measurement data contains a real 
and an imaginary component. A Randles equivalent circuit can be fitted to the 
impedance data as a function of the frequency obtained through EIS 
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measurement, as shown in Figure 1 [26-29]. Here, Rs is the resistance of the 
bulk solution, Zw is the Warburg impedance that comes about as a result of the 
diffusion of ions in the solution between the electrodes. CDL is the double layer 
capacitance, and RET is the electron transfer resistance.
 Fig 1. Randles equivalent circuit for Nyquist plot obtained from electrochemical impedance 
spectroscopy.
! Rs and Zw are affected solely by the bulk solution. As such, these values 
will not vary with electrical activity occurring at the solution/electrode interface. 
CDL and RET on the other hand are dependent on the dielectric and the electron 
transfer resistance at the electrode interface, respectively. There are other circuit 
models that can be fitted to EIS data, but the Randles circuit is the most common 
choice and it is the one used during data analysis in the research described in 
the following chapters.
 ! EIS has proven to be a sensitive method that can detect even minute 
changes in the capacitance and resistance of the transducer-bioactive layer 
interface [30,31]. The data can be collected in the presence of a redox probe. 
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This measurement is called faradaic impedance spectroscopy and it is used to 
probe the biocatalytic reactions between the modified transducer and the 
captured target. The total electron transfer resistance, RET, of the system in this 
case is equal to the contributions from the electron transfer resistance due to the 
electrode itself, which is constant, and the electron transfer resistance from the 
redox probe, which is variable [32]. The CDL, or double-layer capacitance, can be 
found the same way, by adding the inverses of the capacitive contributions from 
the electrode itself and its surface modifier and then taking the inverse of that.
! EIS spectra can also be obtained without the use of a redox probe. This is 
called nonfaradaic impedance spectroscopy. In this case, the CDL values can be 
exclusively investigated without taking the other circuit elements into account 
[32,33]. The circuit elements that arise due to the presence of a redox probe, RET 
and Zw, can be assumed to be infinite, leaving a simplified circuit, with just the RS 
and CDL components in series. However, there needs to be no such assumption 
and values for RET and Zw may be obtained using the circuit in Figure 1. 
! A common method to determine the values of the above four parameters 
of the system is to gather EIS data, plot the imaginary and real components of 
the impedance, and fit the resulting curve with circuit fitting software. One such 
example of this software is Z-view. The resulting curve is called a Nyquist plot as 
seen in Figure 2. Figure 3 provides an overview of the interactions occurring 
around the transducer and how those interactions align with the Randles circuit 
and Nyquist plot.
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! Another method of using EIS data is to analyze the individual impedance 
measurements obtained at each frequency. The individual impedance values 
recorded under different conditions can be compared as long as they are at the 
same frequency.  Frequencies between 50 and 5000 Hz produce the most linear 
signal for change in impedance under different conditions. An example of this 
type of data analysis would be to compare the change in impedance at a 
particular frequency for increasing concentrations of the molecule that is being 
detected and determining if there is a correlation.
Fig 2. An example of a Nyquist plot obtained through EIS data. The semicircular portion of the 
graph is a result of the high frequency response of the system while the linear portion of the 
graph is generated from the low frequency response. The higher frequencies in the spectrum 
allow the fast events such as electron transport to be examined and the lower frequencies are a 
response of slower events such as mass transfer due to diffusion. 
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Fig 3. Summary of interactions occurring at electrode surface when binding is taking place 
between the sensing layer on the electrode and their alignment with the Randles circuit 
components. Immediately around the electrodeʼs area is where the values for the CDL and RET 
components are determined. In the diffusion layer there is still some ion flow and the ZW 
component dominates. Farthest out from the electrode is the bulk solution, RS. The Nyquist plot 
summarizes which components of the Randles circuit can be determined from the plot.
1.4 EIS sensors in literature. The first impedimetric sensor was developed in 
1986 [34] and the next followed in 1988 [35]. Many of these early sensors 
consisted of an insulator or polymer containing the probe molecule being layered 
on the interdigitated electrodes of the sensor. The resulting change in impedance 
was measured when the probe moleculeʼs complementary molecule was 
detected by the sensing layer. The first immunosensor utilizing EIS as the 
detection method was reported in 1991 [36]. The biosensor was sensitive down 
to a concentration of 50 ng/mL of human antiIgG. 
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! Self-assembled monolayer (SAM) modified electrodes were reported in 
1997 [37]. Mirsky et al. monitored the impedance changes that occurred during 
probe molecule immobilization onto the SAM for different probe densities. The 
change in impedance was measured at 20 Hz where the change in impedance 
was purely capacitive. By making these measurements they were able to 
improve signal reproducibility by 10-30%.
! In 1996, Rickert et al. asserted that nonfaradaic EIS was preferable to 
faradaic detection. Though there was observed nonspecific binding and drift, the 
capacitive measurements reported using nonfaradaic EIS went down to the ng/
mL level [38]. 
! In 2000, an early faradaic EIS sensor was reported on a SAM-modified 
gold electrodes [39]. In it several different routes to sensor functionalization were 
examined by comparing electron transfer resistance values. It was determined 
that it was possible to cover 97% of the electrode with an antibody sensing layer 
and that the addition of a redox probe allowed for detection to the pg/mL level.
! Recently there has been a push to create EIS biosensors capable of 
detecting more than one target at a time to increase the speed and ease of 
detection. A DNA-based sensor was recently developed to detect Pb2+, Ag+, and 
Hg2+ based on their interactions with DNA [40]. They were detected down to 
concentrations of 10 pM, 10 nM, 0.1 nM, respectively, in lake water and calf 
serum.
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! DNA based sensors relying on hybridization between the target and the 
sensing layer have also been growing in popularity. Recently Hassen et al. 
reported the development of a DNA based sensor that implemented streptavidin 
coated magnetic nanoparticles and biotinylated DNA probes to detect HIV and 
HIVB DNA down to concentrations of 160 pmol and 50 pmol respectively [41]. 
! RNA biosensors have also been developed. Park et al. have reported on a 
faradaic EIS sensor detecting a highly conserved region of the RNA genome of 
hepatitis C virus [42]. This particular RNA oligomer was detected down to a level 
of 26 pM.
! A great deal of effort has also been put into developing EIS biosensors 
using novel materials. In 2011, a biosensor was reported that utilized electrodes 
modified with immolized E. coli specific DNA on cystine dendrites [43]. These 
electrodes, using EIS, were able to selectively detect E. coli over other water-
born pathogens over a range of concentrations from 10-14 to 10-6 M. 
! Novel films on electrodes are also drawing attention for their ability to be 
easily incorporated into the sensing layer of an EIS biosensor. One such film 
recently reported by Chen et al. contains polypyrrole, to promote conductivity and 
electrical activity, polypyrrolepropylic acid, to promote hydrophilicity at the same 
time providing covalent bond linkers, and gold nanoparticles, which promote 
stability, conductivity, and covalent bond linkers. This film was functionalized to 
detect human interleukin 5 in spikes phosphate buffered saline (PBS) and 1% 
human serum [44]. The lowest detection level achieved was 10 fg/mL in PBS and 
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1 pg/mL in serum. In both samples, the dynamic range for detection was three 
orders of magnitude. 
!
1.5 Aptamers and their application in biosensors. Aptamers are single 
strands of DNA or RNA that have a unique conformation that can be exploited to 
make them bind to protein targets other than their complementary strands [45, 
46]. They have been used to bind to a large number of targets including aromatic 
ligands, amino acids, oligosaccharides, peptides, proteins, and cells [47, 48]. 
Figure 4 is a rendering of an aptamer bound to a protein [49]. 
Fig 4. Rendering of aptamer-protein binding. The three dimensional structure of the aptamer 
enables it to bind with strong affinity for a particular region of the protein.
!
! The identification of these binding sequences of the strands occurs though 
a selective process called SELEX, selective evolution of ligands by exponential 
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enrichment [45, 46]. The process begins with the selection of binding sequences 
or RNA or DNA from a library of random sequences of known length and end 
sequences. Through well-defined tertiary structure aptamers are able to bind to a 
target molecule. They exhibit dissociation constants in the picomolar and 
nanomolar range which is on the same order as some monoclonal antibodies 
[50]. !
! Aptamers offer many advantages over traditional proteins. They can be 
synthesized cheaply and reliably unlike antibodies. Their overall structure can be 
evaluated, once selected for a target, yielding information about the structure of 
the target protein. They can also be modified chemically to make them more 
stable, to increase their shelf life, or to increase their binding affinity for the 
target. Their simple structure makes it easier to develop them into a sensing layer 
in a device. They are also more stable and less prone to denaturation than 
antibodies. The biggest obstacle to the development of aptamers is their 
reactivity with nucleases. This is primarily a problem with RNA aptamers. As 
such, we will be focusing on DNA aptamers. However, a slight structural 
modification to the ends of the aptamer makes it resistant to interaction with most 
nucleases found in biological samples [51]. 
1.6 Outline of dissertation. This dissertation will cover all procedures and 
results of the research in developing biosensors for the detection of ovarian 
cancer biomarkers. Chapter 2 contains background on the biosensor platform 
16
and the computational models created to improve its design. The results 
obtained from the models will be included along with information about the 
software used to generate the models. Chapter 3 covers the functionalization 
procedure for the biosensors as well as specific details about each of the 
antibody based biosensors that were developed for the detection of CA-125, 
CEA, and He4. Chapter 4 details the procedure used to create an aptamer pool 
for CA-125. Information about the molecular cloning process is also included. 
Chapter 5 deals with the methods and techniques used during the analysis of the 
aptamers obtained during the work done in Chapter 4. Work with sequence 
analysis and ELISAs is included. Chapter 6 contains the results obtained from 
the work detailed in Chapters 3-5. Discussion is included. Chapter 7 is a 
summary of the conclusions drawn from the results in Chapter 6. There are also 
suggestions for future work.
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Chapter 2:
IDEA chips and biosensor device design through computational models
18
2.1 IDEA Chip.  The transducer is a key component of electrochemical 
biosensors. Optimized transducer design and electrolyte composition can lead to 
more sensitive and more effective biosensors. For this project one specific 
transducer based on past investigation design was used, but other configurations 
and variations on the current design were modeled as a way to see where the 
design could be improved. 
! Interdigitated electrode array (IDEA) chips were fabricated using standard 
photolithography techniques at SHARP Labs in Camas, WA. A 650μm thick 
silicon wafer was coated with a layer of silicon dioxide that was 1 μm thick. A thin 
layer of gold was also deposited onto the surface. From there, microelectronic 
photolithography techniques and deep reactive ion etch (DRIE) were used to 
carry out the fabrication process.
! Each IDEA chip consisted of eight electrode arrays, each with its own 
contact pad. The electrode arrays were made of gold, long known to be a 
biologically friendly material. Each array contained 39 individual electrodes 
measuring 1.5 μm wide, 180 μm long, and 0.2 μm high. Electrode fingers were 
separated by a gap measuring 0.8 μm. The eight individual arrays were arranged 
such that they could be viewed as two distinct groups of four electrodes. The 
contact pads of the chip were designed in the secure digital (SD) card format. 
The individual geometries of the IDEAs were surveyed using SEM and AFM. The 
overall geometry of the chip can be seen in Figure 5.
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Fig 5. Several views of the geometry of the IDEA chip. (a) The interlocking electrode fingers each 
with a length of 180μm, (b) Each electrode is 0.2μm high and there is a gap of 0.8μm between 
each of them, (c) the overview of each electrode array, (d) a comprehensive look at the chip with 
the eight IDEAs, (e) an SEM image of the electrodes and (f) an AFM image of the electrodes.
 
! The IDEA chips were pre-cleaned in an oxygen plasma. Under certain 
circumstances, the chips may have been cleaned with a piranha solution, a 
mixture of 3:1 sulfuric acid and hydrogen peroxide which is commonly used as a 
cleaning solution in microelectronics.
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2.2 Computational modeling of the IDEA chip. Electric field and current 
density distribution on our IDEA chips were simulated using Ansoft Maxwell 
software. Maxwell utilizes finite element method analysis to solve 
electromagnetic problems for particular geometries. Though the program has 3D 
capabilities, it was decided for the purposes of this experiment that 2D analysis 
would provide sufficient information. 
! A geometric model identical to the actual IDEA chip was created in 
Maxwell. Phosphate buffered saline (PBS), a commonly used buffer in biological 
applications, was selected as the electrolyte, which has a relative permittivity of 
80 and a bulk conductivity of 0.13 siemens/m. The AC input signal had an 
amplitude voltage of 100 mV and zero degree phase angle with respect to the 
current and at a frequency of 60 Hz. Both the background and excitation voltage 
parameters were consistent with the parameters used in the actual physical 
experiments. The device was assumed to be insulated from any background 
electromagnetic activity.
! Maxwell software solves Maxwell's equations under certain conditions that 
are set in the model. Consider any point denoted by ∇Φ(x,y) that is describing the 
electric potential at each value of x and y where ω is the angular frequency at 
which the potential is oscillating. Then the conditions at this point can be 
described by 
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where J is the current density and D is the electric flux density. This equation can 
be modified to represent the conditions in terms of the electric field E and the 
potential as shown below.
where σ is the conductivity and ε is the permittivity. 
! With each of the eight clusters of electrodes containing 39 individual 
interdigitated electrode fingers, some simplifications were made to the model. 
The cross sections of four individual but interlocking electrodes were simulated. 
In this way, the behavior of electrodes both on the outside edges and in the 
middle of the array were examined. 
! The following limitations were set for the problem solving component of 
Maxwell: 1% error, 100% refinement per pass with a maximum of ten passes and 
a minimum of one converged pass. Using these conditions, a graphical 
representation of the electric field and the current density were obtained. A 
sample of the representation of the electric field can be seen in Figure 6.
! Several variations to the existing design were explored. The effect of the 
gap width between the electrodes, both smaller and larger than the 0.8 μm used 
in the current designs was examined.The electric field and current density that 
resulted from these modifications were evaluated. This includes overall 
distribution as well as evaluation at particular points on the electrodes, namely 
the edges and center, at 10 and 50 nm from the electrode surface. The positions 
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are identified in Figure 7. This allowed the strength of the electric field and 
current density of the resulting modifications to be compared as well as provided 
the values at different positions on the electrodes. In evaluating the field at 
varying distances from the electrode it is possible to evaluate the attenuation or 
augmentation of these parameters with distance.
Fig 6. An example of the simulated electric field distribution surrounding the IDEA electrodes on 
the chip. This is the electric field for an unmodified electrode.
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Fig 7. The four positions on the IDEA chip model that were evaluated for the magnitude of the 
electric field and the current density. All points were evaluated at 10 and 50nm above the 
electrode surface.
! The effect of the height of the electrodes on these parameters was also 
modeled using the same method as was the width of the electrode. Another 
geometric parameter examined was the pitch of the IDEA electrodes. A layer of a 
nonconducting polymer and layers of gold nanoparticles on top of the electrodes 
were also modeled to see if they could amplify the signals generated by the 
electrodes.
 
2.2 Electrode spacing, electrode height, and electrode width models and 
results. The spacing between our fabricated IDEs was 0.8 μm. Modeling was 
used to determine the optimal spacing between the electrodes that would result 
in a stronger electric field as evaluated at the points shown in Figure 7. In total, 
eight different gap widths were modeled. The widths chosen were 0.1, 0.2, 0.3, 
0.5, 0.6, 0.8, 0.9, and 1.0 μm. These values were chosen because they gave a 
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sampling of the electric field and current density values for gap widths both larger 
and smaller than the gap currently used in our fabricated chips. Figure 8 is a 
comparison of the current density for four of the gap distances that were 
modeled. As the gap distance increased, the current density values decreased.
Fig 8. Comparison of current density distributions for four of the modeled gap distances. The four 
gap distances shown are 100, 300, 500, and 1000nm. The current density values decrease for 
increasing gap distances.
!
! The results of the effect on the electric field of the various gap widths can 
be seen in Figure 9. The electric field and current density values exhibit an 
exponential decay for electrode spacings between 100 nm and 600 nm and 
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flatline beyond that distance. As the spacing currently used in the chips is 800 nm 
and in that static region, it was evident that a decrease in gap distance had the 
potential to greatly enhance the electric field and current density values.
Fig 9. Graph of the decline in electric field and current density values with increasing gap 
distance. There is an exponential decay in values between 100 and 600nm after which the values 
become static. All values were obtained at 10nm from the electrode surface. This exponential 
decay was seen at every evaluated point on the electrodes.
! The same effect can be seen in Figure 10. Keeping the width of the 
electrode constant at 1.5 μm and the height of the electrode at 200 nm, the 
electric field values at 10 nm from the electrode surface for gap distances of 100, 
300, and 500 nm increase with decreasing gap distance. Though not shown, the 
effect on the current density values is the same.
! The effect of the electrode height was explored. Heights of 10, 50, 200, 
and 500 nm were modeled. In these model the gap distance was kept at 500 nm 
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and the electrode width kept at 1.5 μm. A gap distance of 500 nm was chosen 
arbitrarily; the purpose of the model was to keep other parameters constant while 
the height of the electrode was altered. The resulting effects on the electric field 
values at a distance of 10 nm from the electrode surface are in Figure 10. The 
electrode height has no effect on the electric field values. Though not shown, the 
effect of the change in electrode height on the current density values is the same; 
there is no change in the values.
! Finally, the effect on the electric field at 10nm from the electrode surface 
for different electrode widths were modeled. Widths of 500, 750, 1000, and 1500 
nm were used while the electrode height was kept constant at 200nm. These 
widths were used with gap distances of 100, 300, and 500 nm. The results can 
be seen in Figure 10. The electric field values are static for every width for every 
gap distance. The electrode width has no effect on the electric field values. 
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Fig 10. Graph of change in electric field values with changes in electrode height, electrode width, 
and gap distance. There is no change in the electric field with a change in electrode height or 
width, but there is an increase in the electric field with decreasing gap distance.
2.3 Pitched electrodes. Two different geometries using pitched electrodes were 
created in Maxwell and the electric field and current density values were 
obtained. The first pitched electrodes had 90 degree edges up to a height of 100 
nm and 45 degree pitch for the remaining 100 nm. Figure 11 contains an image 
of the electrodes as well as the points evaluated for comparison and the resulting 
changes in the electric field and current density at 10 nm from the electrode 
surface. Though not shown, the data from 50 nm from the electrode surface 
exhibits the same trend. 
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Fig 11. Results of first pitched geometry. a) The positions that were evaluated for this geometry. 
b) The electric field and c) current density distributions. d) The electric field and e) current density 
values as evaluated for every point in a) at a distance of 10nm from the electrode surface. The 
electric field and current density values are stronger for the unmodified electrode geometry.
! The second pitched geometry contained electrodes that were pitched at 
45 degree over a height of 200 nm. Figure 12 contains images of the positions 
used to evaluate the impact of such a geometry on the electric field and current 
density values. The data values represented in the graphs were obtained at 10 
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nm from the electrode surface and the values obtained from 50 nm from the 
electrode surface exhibited the same trend.
31
Fig 12. Results of the second pitched geometry. a) The positions that were evaluated for this 
geometry. b) The electric field and c) current density distributions. d) The electric field and e) 
current density values as evaluated for every point in a) at a distance of 10nm from the electrode 
surface. The electric field and current density values are stronger for the unmodified electrode 
geometry.
! Neither of the pitched geometries increased the electric field or current 
density values. They did not largely affect either set of values. It was determined 
that currently used electrode geometry with 90 degree edges was the optimal 
geometry.
2.4 Nonconducting polymer over the electrodes. A model was created in 
which a 100 nm thick layer of polyamide, a nonconducting polymer, was coated 
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on the electrodes and the gap between the electrodes. Polyamide is a polymer 
often used in electrochemical biosensors to bind analytes at the electrodes. It is 
usually developed on the electrodes over a thickness range between 10 and 100 
nm. It has a relative permittivity of 4.3 and a conductivity of 0. The results of the 
effects of the polyamide on the electric field and current density can be seen in 
Figure 13. 
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a)
b)
c)
Fig 13. The results of the nonconducting polyamide layer. a) The positions that were evaluated for 
this model. b) The electric field distribution for the layer. c) The values of the electric field within 
the polyamide layer are enhanced by an order of magnitude. The electric field values in the gap, 
measured beyond the layer, are zero. The polyamide layer has the potential to greatly enhance 
the signal generated by an electrical biosensor.
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! Within the polyamide layer the electric field is greatly enhanced. The 
strength of the field increase by an order of magnitude. This is seen in the 
evaluation of the points outside of the gaps. The points evaluated in the gaps 
show an electric field reduced to zero as they are evaluated in a space not 
contained with the layer of polyamide. This model suggests that a thin layer of 
polyamide would be an effective way to amplify the signal generated by an 
electrical biosensor. Biomolecular interactions take place within 10 to 100 nm of 
the electrode surface. A 100 nm thick layer of polyamide would enhance all 
interactions taking place within this range. 
2.5 Nanoparticle enhancement of electrodes. Nanoparticles, like polyamide 
layers, are a commonly used material to enhance the signal generated by 
electrical biosensors. Several models were created to evaluate the effect on 
these materials on the electric field and current density. The first model was 
based on a single layer of polyamide nanoparticles 20 nm in diameter. The 
nanoparticles were placed all over the electrodes and in the gap at a low density. 
Figure 14 contains the results of the model.
! The nanoparticles enhance the electric field and current density on the 
edge of the exterior electrode, labeled as 4, left in the figure, at a distance of 10 
nm from the electrode surface but the same values for the interior electrode 
edges are reduced. This reduction in values could have a large effect. There are 
37 interior IDEs and only two exterior electrodes. At 50 nm from the electrode 
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surface the electric field and current density values have reached roughly the 
same values and there is no enhancement of either signal observed at the edge 
of the interior electrode. The nanoparticles do not seem to have an effect in the 
gap area. Those positions are evaluated well above the nanoparticle layer and 
are the same for either geometry. 
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Fig 14. The results of a single layer of polyamide nanoparticles at a low density. a) The electric 
field distribution of the nanoparticles. b,d) The electric field and current density values are 
increased at one position at 10nm, but c,e) they are no longer enhanced at a distance of 50nm.
! Next, a higher density of polyamide nanoparticles were placed on the 
electrode surface and in the electrode gaps and the electric field and current 
density values were compared. Figure 15 contains the results at a distance of 50 
nm from the electrode surface. Though the values obtained at 10 nm from the 
electrode surface are not represented in the figure, they follow the same pattern 
as the values obtained at a distance of 50 nm. The addition of the nanoparticles 
greatly reduces the current density values, but enhances the electric field values. 
Polyamide is an insulating polymer so the effect on the current density is to be 
expected.
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Fig 15. Results of a high density single layer of polyamide nanoparticles. a) the electric field 
distribution with b) a closeup. c) The electric field and d) current density values for the evaluated 
points at 50nm. The electric field values are increased while the current density is decreased. 
! A double layer of polyamide nanoparticles on the electrodes and gaps at 
high and low densities were also modeled. The low density results are in Figure 
16 and the high density results are in Figure 17. The current density values are 
lowered by the addition of the low density double layer of nanoparticles. The 
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electric field values for the edge of the exterior electrode are enhanced at a 
distance of 10 nm from the electrode surface, just as they were for the low 
density single layer of polyamide electrodes. However, unlike the low density 
single layer of nanoparticles, the electric field values for the edge of the interior 
electrodes are not reduced. At a distance of 50 nm from the electrode surface the 
electric field values for this low density double layer of nanoparticles reached the 
same magnitude as the electric field values for the unmodified electrodes. The 
current density values are lowered by the addition of the low density double layer 
of nanoparticles. They remain reduced at every evaluated position and at 
distances of 10 nm and 50 nm from the electrode surface.
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Fig 16. Results of double layer of polyamide nanoparticles at low density. a) The electric field 
distribution. b,c) The electric field is enhanced at one position at a distance of 10nm from the 
electrode surface but the values are no longer increased at a distance of 50nm. d,e) The current 
density values are larger without the presence of nanoparticles.
! The electric field values were obtained and compared for a high density 
double layer of nanoparticles at a distance of 10 nm from the electrode surface. 
The values are reduced at every evaluated position. Though not shown, the 
electric field values at a distance of 50 nm exhibited the same trend as did the 
current density values at the same distances. 
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Fig 17. Results of a high density double layer of polyamide nanoparticles. a) The electric field 
distribution and b) the resulting effect on the electric field values at 10nm. The electric field values 
are higher without the presence of nanoparticles.
! The effects on the electric field and current density values were compared 
for single and double layers at low density. The results are in Figure 18.  The 
values are almost identical at distances of 10 and 50 nm indicating that the size 
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of the layer would not have an impact on the signal generated by an electrical 
biosensor.
Fig 18. Comparison of effects from single and double layers of polyamide nanoparticles at low 
density. a,b,c,d) There is not an appreciable change in the electric field or current density values 
at any distance from the electrode surface.
! The effects of the single and double nanoparticle layers at a high density 
were also compared as seen in Figure 19. Though data is only shown for 50 nm 
above the electrode surface, the data from 10nm above the electrode surface 
exhibits the same trend. At every point the single layer of nanoparticles creates a 
stronger electric field and current density than the double layer. This is a 
departure from the behavior observed for the single and double layers at low 
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densities. At the lower density, the size of the layer has little to no effect on the 
electric field and current density.
Fig 19. Comparison of effects from single and double layers of polyamide nanoparticles at high 
density. a,b) The electric field and current density values are higher for a single layer of 
nanoparticles.
! It was necessary to determine if a low density or high density layer, 
regardless if the nanoparticles are in single or double layer, has a greater impact 
on the electric field and current density values. Figure 20 compares these values 
at a distance of 50 nm from the electrode surface. Though not shown, the data 
obtained at 10 nm from the electrode surface exhibited the same trend. At every 
position a low density layer of nanoparticles has a greater effect than a high 
density layer.
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Fig 20. Comparison of high and low density polyamide nanoparticles. a,b) The electric field and 
current density values are greater for a low density of nanoparticles.
! Many models were created to evaluate the effect of nanoparticles on the 
electrical biosensor. From the observed effect on the electric field and current 
density values, it was determined that polyamide nanoparticles 20 nm in 
diameter are not capable of consistently enhancing the signal generated by the 
biosensor. Should these nanoparticles be used, the best use of them should be 
in a single layer at a low density.
2.6 Indirect confirmation. Based on the results of the computational models 
created using Ansoft, it was clear that some small modifications to the basic 
electrode array design would greatly enhance the sensors sensitivity.
! The modification that would have the largest impact was decreasing the 
gap between the interdigitated electrodes. IDEAs were fabricated using electron 
beam lithography for gap distances of 200, 300, 400, and 500 nm. Figure 21 
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represents the sensitivity of the fabricated devices. D2 (width of 400nm, gap of 
200nm) was the most sensitive and D6 (width of 1500nm, gap of 500nm) was the 
least sensitive. D3 was fabricated with a width of 400nm and a gap of 400nm, 
making it comparable to D2. D4 (width of 700nm, gap of 200nm) and D5 (width of 
700nm, gap of 300nm) were comparable to each other. In creating two devices 
with the same width and different gap sizes it was possible to directly compare 
the effect of the gap size. D6 was the device most closely resembling the 
dimensions used in the IDEs fabricated by SHARP.
! RCT values for each device were obtained from Nyquist plots created from 
the sensorsʼ impedance response under different concentrations of a redox 
probe. The Nyquist plots were fitted with Randles circuit using Z-view. These RCT 
values were plotted for each concentration for each device. A linear fit was 
obtained for each deviceʼs response. The slope of this line was divided by the 
area of the device. The resulting value was the aerial sensitivity of the device.
! D2 had the highest aerial sensitivity value. It had a higher sensitivity than 
D3 which had the same width as D2 but twice the gap distance of D2 proving that 
a smaller gap size is key to more sensitive detection. The same result was seen 
for devices D4 and D5. Those devices had the same width but D4 had a smaller 
gap size by 100nm and it resulted in a higher aerial sensitivity value for D4 than 
the value for D5. D6 was the least sensitive device and it had the largest gap size 
at 500nm. The width of D6 was the same as the IDEs fabricated by SHARP but 
its gap size was 300nm less than the SHARP IDEs. This implies that the SHARP 
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IDEs are less sensitive than any of the devices fabricated to verify the modeling 
results from section 2.2. 
  Fig 21. Determination of sensitivity of the devices fabricated through e-beam lithography. (a) RCT 
values plotted against the redox probe concentrations. For all devices, the slopes of the curves 
were determined from the best fit equations (shown as a straight lines only for devices D2 and D6 
for clarity) for each curve (shown in the legend) and is termed device sensitivity. (b) Relative 
aerial sensitivities (slope per unit area) of different devices D2-D6. D2 has the highest aerial 
sensitivity value and D6 has the lowest aerial sensitivity value.
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Chapter 3:
Biosensor functionalization and immunosensor development
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3.1 IDEA chip functionalization procedure. In order for the binding event to 
occur between the target and the probe molecule an adequate sensing layer had 
to be developed on the electrodes on the IDEA chip. Figure 22 is a diagram of 
the functionalization process.
! The first step consisted of covering the IDEs with a self-assembled 
monolayer (SAM) of molecules. This was achieved by submerging the chips in a 
SAM solution of 100 mM cysteamine hydrochloride (Sigma Aldrich, St. Louis, 
MO) in 95% ethanol overnight. 
! Following this step, the chips were washed in a copious amount of 95% 
ethanol three to five times for five minutes at a time, followed by a 10 minute 
wash in DI water. Next, the chips were incubated on an orbital shaker in a 10 mM 
solution of triethylamine (Sigma Aldrich, St. Louis, MO) in DI water for an hour. 
Subsequently, they were washed in copious amounts of DI water, three to five 
times for five minutes each time. The SAM layer was then activated by placing 
the chips in a 2.5% aqueous solution of glutraldehyde (Fisher Scientific, Fair 
Lawn, NJ) in PBS for two hours on an orbital shaker. The chips were then 
washed in a copious amount of 0.1 M carbonate-bicarbonate buffer in DI water 
three to five times for five minutes each time. Subsequent to their washing, the 
chips were dried under nitrogen stream.
!      The next step was to anchor the probe molecule. A solution containing 
the probe in carbonate/bicarbonate buffer was placed on the electrodes and 
allowed to evaporate overnight. Using the glutraldehyde linker, the probes were 
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immobilized onto the chip. Following this evaporation procedure, any unbound 
protein was washed away in three to five washings of five minutes apiece using 
the carbonate-bicarbonate buffer previously mentioned. During the next step, the 
unreacted aldehyde groups on the SAM were neutralized, and thus the 
conjugation reaction stopped, when the chips were placed in a 5% solution of 
ethanolamine (Sigma Aldrich, St. Louis, MO) in 0.1 M carbonate-bicarbonate 
buffer for one hour. Again, the chips were placed on an orbital shaker during this 
incubation period. After this step of the process is completed, the chips were 
washed with PBS containing 0.05% Tween 20 (PBST) following the same 
procedure as previously mentioned.
! Finally, the nonspecific binding sites, or the areas on the electrodes that 
did not have a probe molecule immobilized onto them but were still available for 
binding activity, were blocked using a 1% solution of polyvinylpyrrolidone (PVP), 
a non-protein polymer,(Sigma Aldrich, St. Louis, MO) in PBST. The chips were 
placed on an orbital shaker in this blocking solution for an hour. PVP lends itself 
to being an ideal blocking solution as it has thin layer formation, aqueous 
solubility, and biocompatibility.
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 Fig 22. Overview of functionalization process. A SAM is developed on the gold electrodes and 
activated using triethylamine and glutraldehyde. The capture protein is attached to the SAM and 
the nonspecific binding sites are blocked using 1% PVP. Image is not to scale.
! At this point, the functionalization procedure was complete. Any chips not 
immediately used after this final step were stored in PBST at 4°C where they 
remained viable for 24-48 hours.
3.2 EIS measurements. The impedance measurements were made using an 
impedance meter (HP Agilent 4294A). Using software that was written to control 
the impedance meter, the electrical impedance spectroscopy (EIS) data was 
collected over a range of 50 Hz to 500 kHz three times at a constant voltage of 
25 mV without DC bias when nonfaradaic data was being collected and with a 
215 mV DC bias when the faradaic data was being collected. These three sets of 
data were averaged at every frequency every time a new set of data was taken 
on an electrode.
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! To begin the experiment, the chip was placed on a clean stage. A 
microfluidic channel made of Plexiglas was clamped on the chip using a gasket 
made of PDMS for easy handling of solutions and effective shielding of 
connectors from the measurement chamber. Two tubes attached to the Plexiglas 
channel allowed the fluid to enter and exit the channel and kept the fluid localized 
to the functionalized electrodes. Data was then collected by a probe station 
connected to the impedance analyzer. Figure 23 demonstrates the placement of 
the chip, gasket, and channel on the stage.
 
Fig 23. IDEA chip placed on a clean stage. The PDMS gasket and plexiglass channel are 
securely placed over the electrodes on the IDEA. The tube leads in and out of the channel allow 
for the liquid sample to be injected into the area directly surrounding the electrodes.
!
! The EIS data was taken in PBST buffer solution. Data was collected 
before the beginning of the experiment, during the experiment as the sensor was 
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incubated with varying concentrations of the target antigen or antigens for ten 
minutes, and after the channel on the chip was flushed through with a 
regenerating buffer solution of pH 2.00 from La-Mar-Ka (Baton Rouge, 
Louisiana). This buffer removed any bound molecules from the sensing layer. 
The three sweeps of data were averaged to form one set of data that contained 
the average impedance, including both its real and imaginary parts, and phase 
angle. The data was analyzed using Open Office Spreadsheet.
! In this research, two methods of data analysis were used. They are both 
outlined in section 1.3, but they will be briefly outlined again below. One of the 
ways the data was analyzed was to directly compare the impedance 
measurements obtained after every set of data collection. One frequency was 
chosen, generally one between 50 Hz and 5 kHz, and the impedance 
measurement that resulted from one concentration binding to the sensing layer at 
that frequency is compared to the other impedance measurements obtained from 
the other concentrations at the same frequency. This resulted in a concentration 
dependent response.
! A second way of analyzing the EIS data was to develop and analyze 
Nyquist plots. Nyquist plots were obtained using the real and imaginary 
components of the impedance. The data plots from the native electrode, after 
SAM layer formation, electrode with the capture antibodies, and electrode after 
antigen binding activities between the biolayer and the target molecule all serve 
to show that the biomolecular mass accumulation, at the electrode surface, was 
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increasing with each subsequent step in the functionalization and experimental 
procedure. The data obtained was fitted with a Randels equivalent circuit using 
Zview software commercially available from Scribner Associates (Southern 
Pines, North Carolina), and the numerical values obtained for the electron 
transfer resistance and double layer capacitance were compared.
3.3 CA-125 biosensor. A biosensor, created using the procedure described in 
section 3.1, was developed for the detection of ovarian cancer biomarker 
CA-125. EIS was used to measure the binding between CA-125 and the sensing 
layer on the device. 
! Monoclonal antibodies for CA-125 were purchased from US Biological 
(Swampscott, MA). antiCA-125 at a concentration of 50 μg/mL in carbonate/
bicarbonate buffer were anchored onto the chip by placing the solution over the 
electrodes and allowing it to evaporate overnight. The rest of the functionalization 
procedure was executed exactly as described in section 3.1.
! After the sensing layer was activated and the nonspecific binding sites 
blocked, the chip was exposed to PBST spiked with CA-125 at concentrations of 
10, 20, 40, and 80 U/mL to cover the clinically relevant concentrations. The cutoff 
concentration of CA-125 that indicates disease is 35 U/mL. CA-125 was injected 
into the channel and allowed ten minutes to bind to the sensing layer before the 
excess, unbound CA-125 was washed out of the channel using PBST and the 
EIS data collected.
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! For these experiments, the change in impedance due to antigen binding 
was compared at different concentrations. Baseline data was determined using 
the average impedance values before any binding of the target protein to the 
sensing layer and after regeneration of the chip when the bound proteins are 
removed from the sensing layer. 
! The sensor was also used to detect CA-125 concentration in 5% rabbit 
serum. The serum solution was created in PBST with 5% of the volume being 
rabbit serum. Again, the serum solution was spiked with CA-125 at 
concentrations of 10, 20, 40, and 80 U/mL. The data was collected and analyzed 
in the same way as the measurements made in spiked buffer solution.
3.4 CEA biosensor. Following the procedure in section 3.1, monoclonal 
antibodies to CEA, also purchased from US Biological, were anchored onto the 
IDEA chip at a concentration of 50 μg/mL by allowing the antibody solution to 
evaporate overnight. The sensing layer was activated and the nonspecific 
binding sites were blocked. EIS was used to make the device measurements. 
! The device was exposed to CEA in concentrations ranging from 1 pg/mL 
to 10 μg/mL in 10 fold concentration increments in PBST to cover a broad range. 
The cutoff for clinical diagnosis of disease is 10 ng/mL in serum. These 
concentrations were present in spiked buffer and in the same 5% serum solution 
described in section 3.3. In both spiked buffer and serum, CEA was given ten 
minutes to bind with the sensing layer before any unbound CEA was removed 
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using PBST flushed through the channel and the EIS data collected. The data 
was obtained and analyzed as described in section 3.2
! Three sets of data were collected on the sensors created for the detection 
of CA-125: the initial data before any binding to the sensing layer occurred, the 
binding data from the binding between the sensing layer and CA-125, and the 
final data that was a result of the low pH regeneration buffer removing any bound 
CA-125 from the sensing layer.
3.5 Multiplexed biosensor for the detection of CA-125 and CEA. A biosensor 
capable of detecting both CA-125 and CEA was developed following the basic 
protocol outlined in section 3.1. A PDMS gasket that effectively separated the 
eight interdigitated electrodes into two groups of four was placed on the IDEA 
chip. Four of these electrodes had a solution containing 50 μg/mL of monoclonal 
CA-125 antibodies placed over them and the remaining four electrodes had a 50 
μg/mL solution of monoclonal CEA antibodies placed over them. Both solutions 
were allowed to evaporate onto the chips overnight. Figure 24 is a diagram of the 
functionalization of the multiplexed chip.
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 Fig 24. Overview of functionalized multiplexed chip. a) Electrodes are functionalized for the 
specific capture of different antigens. b) A serum sample containing target antigens for both 
electrodes is exposed to the sensing layers on the electrodes, c) the target antigen for each 
electrode binds to the electrodes, and d) the unbound antigens are washed away. Image is not to 
scale.
! Spiked PBST containing 10, 20, 40 and 80 U/mL of CA-125 and 1, 10, and 
100 ng/mL of CEA was detected by the multiplexed sensor. The same 5% rabbit 
serum solution as described in section 3.3 was also spiked with CA-125 
concentrations of 20 and 40 U/mL and CEA concentrations of 10 and 100 ng/mL 
and detected by the sensor. The data was again analyzed using the methods 
detailed in section 3.2. 
! In all cases, the target antigen was allowed ten minutes to bind to the 
sensing layer before any unbound protein was washed from the channel with 
PBST and EIS data was collected. A total of three sets of data were collected 
from these biosensors: the initial data before any binding to the sensing layer 
occurred, the binding data that resulted from the attachment of CA-125 or CEA to 
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the sensing layer, and the final data that was collected after the regeneration 
buffer removed the bound protein from the sensing layer.
! The multiplexed chip had a unique advantage built into its design. When 
binding data for one of the proteins was collected, it was collected on every 
electrode regardless of whether the electrodes were functionalized for its 
detection or not. In doing this, a built-in mechanism to check the specificity of the 
functionalized electrodes was created. Figure 25 is a diagram representing the 
binding between the electrodes and their specified antigen targets.
 Fig 25. Diagram representing electrodes functionalized for the detection of different targets. A 
sample containing either CA-125 or CEA was given time to bind to all the electrodes whether they 
were specified for its detection or not. After the unbound antigen was washed away EIS data was 
collected on all the electrodes. In doing this the specificity of the functionalized electrodes could 
be qualified. Image is not to scale.
! For example, when CA-125 was captured by the sensor, the binding data 
collected from electrodes functionalized specifically for the detection of CA-125 
was compared to the binding data collected from the electrodes specifically 
functionalized for the detection of CEA. This process was repeated during the 
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detection of CEA. In doing this it was possible to determine the extent of the 
specificity exhibited by each set of electrodes for its target protein. Specific and 
nonspecific detection by each set of electrodes was quantified.
! The multiplexed sensor offered a distinct advantage over the sensors 
developed for the detection of CA-125 and CEA alone. CA-125 and CEA alone 
are unsuitable for early detection of ovarian cancer because neither is always 
present at elevated levels in patients and is also indicated in other non-ovarian 
cancers. Also, neither is present at elevated level in all three types of ovarian 
cancer. 
! CA-125 and CEA are both effective at determining the effectiveness of 
treatment and detecting both simultaneously promises to give more sensitive 
feedback about the treatment course. By creating a multiplexed sensor, it is 
possible to more comprehensively detect ovarian cancerʼs fingerprint and 
produce fewer false positives for the disease. The thought is that if both CA-125 
and CEA are detected at elevated levels in one patient sample the likelihood of 
correctly diagnosing ovarian cancer at an early stage will be increase.
3.6 He4 biosensor. There were two biosensors developed for the detection of 
He4 and they both differed from the sensors developed for the detection of 
CA-125 and CEA in several ways. The He4 sensors relied on labels whereas the 
CA-125 and CEA biosensors are label-free. One of the sensors utilized a 
secondary antibody as a label and the other sensor included a biotinylated 
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secondary antibody and additional binding with streptavidin and horseradish 
peroxidase (HRP) and enzymatic activity by HRP with a substrate to enhance the 
biosensorʼs signal.
! The data gathered from the He4 sensors is also different from the data 
obtained from the CA-125 and CEA sensors in that it was taken in the presence 
of a redox probe. This is the faradaic EIS and for both of the He4 biosensors all 
data was collected in the presence of a redox buffer called PBSR (2.5 mM 
potassium ferrocyanide (K4[Fe(CN)6]⋅3H2o), 2.5 mM potassium ferricyanide (K3
[Fe(CN)6], 0.1 M KCl, and PBS). This redox buffer is oxidized and reduced by 
electron transfer from the metal electrodes.  To keep the redox species from 
being depleted the data was gathered under a DC bias condition of 215 mV.
! He4 and two types of monoclonal antibodies were obtained from Abnova 
(Taipei City, Taiwan). A 25 μg/mL solution of the monoclonal antibodies deemed 
suitable for capture by the manufacturer was evaporated onto the IDEA chip as in 
section 3.3. The IDEA chip was functionalized according to the protocol in section 
3.1.
! The He4 biosensor was developed to detect an immunocomplex 
composed of He4 antigen and a secondary antibody that are already bound 
together. A variable concentration of He4 antigen was combined, in PBST, with a 
secondary detection antibody, as determined by the manufacturer, the 
concentration of which was held steady at 10 μg/mL. The antigen and the 
antibodies were allowed ten minutes to bind before being injected into the 
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channel over the IDEA chip. The immunocomplexes were created using antigen 
concentrations of 1.5, 3.125, 6.25, 12.5, 25, 50, and 100 ng/mL, all of which are 
in the currently determined diseased range for ovarian cancer.
! The immunocomplex was given ten minutes to bind to the sensing layer 
before any unbound material was washed from the channel with PBST/PBSR 
and the data was collected. 
! In using the secondary antibody it was possible to generate a larger signal 
from the biosensor as presumably there would be more material bound to the 
sensing layer. It offers the advantages of amplifying the signal without altering the 
functional and binding abilities like a label can do. By holding the concentration of 
the secondary antibody steady and altering the antigen concentration it was still 
possible to directly correlate the signal generated by the sensor to the 
concentration of He4 bound to the sensing layer. 
! A total of three sets of EIS data were collected for these biosensors: the 
initial data before any attachment to the sensing layer, the binding data when the 
immunocomplex had bound to the layer, and the final data after the bound 
immunocomplexes were removed from the sensing layer by the low pH 
regeneration buffer.
! Another biosensor for the detection of He4 using the same premise of 
attaching more material to the sensing layer was also developed. In this sensor, 
the monoclonal antibody suitable for capture, again at 25 μg/mL, was evaporated 
onto the electrodes overnight and functionalized following the protocol in section 
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3.1. Immunocomplexes containing 1.5, 3.125, 6.25, 12.5, 50, and 100 ng/mL of 
He4 combined with a biotinylated secondary antibody at a concentration of 10 
μg/mL were created after allowing the two components to bind for ten minutes. 
Figure 26 is a diagram of the biolayer developed on the sensing layer.
! The biotinylated immunocomplexes were given ten minutes to bind to the 
sensing layer before the unbound complexes were washed away with PBST/
PBSR and the data collected.
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 Fig 26. Diagram of the biolayer developed on the electrode of the He4 sensor. On top of the 
sensing layer, which includes the SAM and capture antibody, the He4 antigen, already bound to 
the biotinylated secondary antibody, is bound. Next the streptavidin-HRP conjugate is introduced 
and it binds to the biotin on the secondary antibody, leaving the HRP ready for activity. Image is 
not to scale.
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! Biotinylated secondary antibodies were obtained from the University of 
Washington (Seattle, WA). Biotinylation is achieved by the addition of several 
biotin molecules at the primary amine sites of an antibody. Streptavidin is a 
natural binding partner of biotin; the dissociation constant of streptavidin-biotin 
binding is about 1014 mol/L, making it one of the strongest non-covalent 
interactions in nature [52]. The streptavidin-biotin complex is resistant to heat, pH 
change, and interactions with solvents and denaturing agents. Because of this, it 
is commonly used in biotechnology applications.
! The biotinylation of the secondary antibody allowed for the formation of yet 
another binding layer, this one achieved by the incubation of 1 μg/mL of 
streptavidin conjugated with horseradish peroxidase (US Biological, Swampscott, 
MA) (HRP) over a period of ten minutes. After that, excess streptavidin-HRP was 
washed from the channel using PBST/PBSR and data was collected. HRP is an 
enzyme that is commonly used in biochemical situations that require signal 
amplification. When in the presence of a substrate containing hydrogen peroxide 
as the oxidizing agent, HRP produces a visible color change, in the case of 
ELISA, or a precipitable product, in the case of membranes, directly correlated 
the amount of HRP present. 
! The streptavidin bound to the biotin and the HRP was available for activity. 
A TMB substrate specific for interaction with HRP, purchased from Sigma Aldrich 
(St. Louis, MO) was injected into the channel on the chip and given five minutes 
to react with the HRP. This particular substrate is for use in situations that require 
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the formation of a precipitate. After five minutes EIS data was collected without 
washing the channel. 
! A total of four sets of EIS data was collected from these biosensors: the 
initial data before the incubation of any proteins, the first set of binding data 
between the biotinylated immunocomplex and the sensing layer, the second set 
of binding data between the streptavidin-HRP and the biotinylated 
immunocomplex, and the third and final set of binding data that was a result of 
the formation of the precipitate from the HRP-substrate interaction. 
!
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Chapter 4:
Aptamer selection and molecular cloning procedures
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4.1 Modified SELEX procedure for aptamer selection and identification. The 
traditional method of aptamer selection, SELEX, relies on radioactive labels to 
identify the sequence of the binding strand of DNA. As such, this method calls for 
an isotope laboratory to carry out the experiment, as well as an overall elevated 
level of caution and cost.
! A slight modification to the procedure eliminates any need for such 
restrictions. By simply amplifying the binding sequence using polymerase chain 
reaction (PCR) described in the following section 4.2, a fluorescent label can be 
introduced that allows for identification of the binding sequence [53]. This label is 
incorporated into one of the primers used to run the PCR. The other primer used 
in the PCR process that binds to the strand complementary to the binding 
sequence also contains a label. This label is a sequence of 18 adenine 
nucleotides, called a poly A, that cause that product to be 18 nucleotides longer 
than the binding strand. In this way we have two different sized PCR products 
with the binding sequences easily identifiable by their fluorescent label and the 
non-binding but complementary strand identifiable by its length as seen in Figure 
27.
! The process begins by immobilizing the target protein on a nitrocellulose 
membrane. An overview of the entire process can be seen in Figure 28. The 
target is whatever protein for which the researcher is trying to find an aptamer. 
After immobilization, the membrane is washed in a buffer conducive to binding. In 
the same buffer a quantity of a random DNA library, containing about 460 different 
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sequences with known ends, is introduced to the membrane. Binding is allowed 
to continue for two hours. After two hours, any remaining unbound sequences 
are removed and any sequences that bind to the target are eluted from the 
membrane. These sequences are then amplified using PCR with the 
aforementioned modified primers.
Fig 27. The double stranded PCR product from the modified SELEX procedure after being run 
through a denaturing polyacrylamide gel. The shorter strand, identified by the red box and its 
relative position to the two DNA ladders, is the known binding sequence and it's longer 
complementary product is located above it. The binding strand is excised from the gel, the DNA 
eluted from it, and the DNA sequences contained within used in the next SELEX round. The blue 
boxes indicate the primers the remaining primers that have not been used by the PCR reaction. 
The top blue box contains the longer primer with the poly A and the bottom blue box contains the 
smaller primer with the FITC label. As measured against the DNA ladder, the longer primer is 
twice the length of the FITC labeled primer. This gel has been stained with ethidium bromide so 
that both PCR products are visible.
!
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! ! After amplification, the double stranded PCR products are 
separated and run through a denaturing polyacrylamide gel. Gel electrophoresis 
is described below in section 4.3. Due to the fluorescent label, the binding 
sequence is easily identified in the gel using UV illumination. The band of binding 
sequences is excised from the gel with the longer complementary strand left 
behind. The binding DNA is eluted from the gel and those binding sequences are 
used in the next round of selection against the membrane containing the 
immobilized target. 
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Fig 28. Overview of SELEX process. a) A nitrocellulose membrane spotted with CA-125 is 
exposed to a random ssDNA library. Some aptamers bind to the CA-125 on the membrane and 
the ones that do not bind are washed away. b) The centers of the membrane spots containing the 
bound aptamers are excised and those aptamers removed from the CA-125. Those aptamers are 
run through a PCR to amplify them. c) The aptamer pool is run through a denaturing 
polyacrylamide gel and the PCR products are separated with the longer, complimentary strands 
to the aptamers (red) produced by the PCR located above the amplified binding strands (green 
and purple). d) The aptamers are excised from the gel, purified and isolated, and used in the next 
SELEX round where they are exposed to a nitrocellulose membrane spotted with CA-125.
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! Typically several rounds of this selection process are carried out, with 
somewhere around ten being standard. It is also a good idea to carry out a few 
rounds of counter selection against a different target protein. The binding 
sequences collected after ten rounds of selection are collected and exposed to a 
different protein immobilized on a membrane. Several of these counter selection 
rounds are carried out with any sequences that bind to the counter selective 
target being removed from the pool of binding sequences.These specific binding 
sequences are then cloned with bacteria.The cloning process is described below 
in section 4.4.  Colonies are picked and the DNA extracted from them and 
purified. Sequencing follows and, ideally, several different binding sequences are 
returned.
! Once the sequences are known their binding capabilities must be 
explored. Attaching a fluorescent label to the different binding sequences is one 
method that allows for easy quantification in binding assays. By measuring the 
fluorescence that results from direct binding between the sequence and the 
target it is possible to evaluate the relative binding capabilities of the known 
sequences. Also using the fluorescence as a relative quantification tool, a 
competitive binding assay can be carried out using the binding sequence and the 
target protein's actual complementary protein. This assessment is an effective 
tool for comparing the binding of the DNA to the binding of the protein's natural 
binding partner. Dissociation constants can also be measured as a way to 
compare the binding ability of the different sequences. 
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! For this research, an aptamer specific to CA-125 was selected using this 
modified SELEX process. The goal was to replace the CA-125 monoclonal 
antibody used as the capture mechanism currently used in the electronic 
biosensor with the selected aptamer.
4.2 Polymerase chain reaction. Polymerase chain reaction, PCR, is the best in 
vitro method to amplify DNA. While molecular cloning produces large quantities 
of amplified DNA, PCR is able to amplify DNA even when it is impure or present 
in very low quantities. PCR is characterized by a relatively simple three step 
process. First, the DNA templates are heated to denature the DNA so that all 
strands are separated. Next, the templates are cooled to allow hydrogen bonds 
to form between the primers and the ends of the template. Finally, the templates 
are heated to a high enough temperature that a DNA polymerase enzyme 
becomes active and adds nucleotides to the 3ʼ end of the DNA, creating new, 
complete strands of DNA. This three step cycle is then repeated as many times 
as necessary, usually between 20 and 30 rounds. Because every cycle results in 
the doubling of the DNA strands, the addition of a few cycles results in a large 
increase in the amount of PCR products.
! The key to running a PCR is to have DNA templates with known 
sequences at the 5ʼ and 3ʼ ends. By knowing these sequences, complimentary 
primers can be used to bind to the template and extend the sequence from the 5ʼ 
end to the 3ʼ end of the unknown part of the template, thus amplifying the DNA by 
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creating new strands of it. The DNA polymerase is also an important part of the 
PCR process.  Most enzymes are destroyed by high levels of heat therefore a 
heat-stable polymerase must be used.
! The conditions for PCR must be determined for efficient and specific 
amplification. Generally the heating temperature is above 90˚C to ensure 
complete denaturation of any double stranded DNA. The annealing temperature 
is unique to each sequence amplification; as it is the temperature at which the 
primers bind to the 5ʼ and 3ʼ ends, it is determined by the nucleic acid 
composition of the primers. The final elongation temperature at which the 
polymerase adds nucleotides to the forming sequence is usually 72˚C. This is the 
temperature at which most polymerases are active.
! The PCR cycles at these temperatures are carried out in a short amount 
of time; 30 seconds to a minute is standard with longer sequences requiring 
more time at each step. 
! Finally, after all cycles are completed the PCR products go through a 
period of extension time at 72˚C for ten minutes. The PCR products can then be 
stored at -20˚C until they are of further use.
4.3 Gel electrophoresis. Gel electrophoresis is a common molecular biology 
technique used to separate proteins and DNA based on their weight and charge. 
The gel acts a sieve of polymer fibers. The size of the pores within the fibers are 
directly related to the gelʼs chemical composition. As the gel electrophoresis 
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experiments described in this dissertation were done using DNA samples, the 
discussion on the technique will be limited to its use in DNA applications.
! DNA is negatively charged and as current is supplied to the gel, the DNA 
moves towards the positive terminal through the pores in the gel. Longer DNA 
sequences are more impeded by the fibers in the gel than shorter sequences and 
the shorter sequences migrate through the gel more quickly. This allows DNA 
sequences of different sizes to be effectively separated. 
! The two primary reagents used to create gels used in electrophoresis are 
agarose and polyacrylamide. Agarose gels are helpful in distinguishing between 
long DNA sequences and sequences that vary greatly in size. Agarose gels are 
run horizontally in TAE buffer containing 40 mM Tris, 20 mM acetic acid, and 1 
mM EDTA. Polyacrylamide gels can be used to distinguish between DNA 
sequences only differing in size by a few nucleotides even if the sequences 
themselves are relatively short. Polyacrylamide gels are run vertically in TBE 
buffer containing 89mM Tris, 89 mM boric acid, and 2 mM EDTA. Polyacrylamide 
gels offer an advantage in that they can be made to be denaturing by the addition 
of a denaturing reagent such as urea or formamide. This denaturing property of 
the gels is what enables the identification of a denatured PCR product where the 
sequences differ in length by only a few nucleotides.
! It is necessary to track the DNA sampleʼs progress as it migrates through 
the gel so that the sample doesnʼt migrate completely out of the gel. One way to 
do this is to include dye in the buffer used to load the sample. Common choices 
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include xylene cyanol, bromophenol blue, and orange G. These dyes usually 
contain a small amount of glycerol to weigh the DNA sample down so that it stays 
in the well of the gel before the power supply is turned on and the sample begins 
to move through the gel. The dyes move more quickly through the gel than the 
sample; as the dye reaches the end of the gel, the sample is still safely inside the 
gel.
! Base pair ladders and mass ladders can be used in conjunction with gel 
electrophoresis to quantify the size or weight of the DNA sample that has under 
gone electrophoresis. The ladder is loaded into one of the wells in the gel and 
run through the gel parallel to the sample. After the gel has finished running, the 
sample bands and the bands comprising the ladder are visualized and 
compared. By doing this the size and the weight of the sample can be verified. 
! Identifying DNA in a gel usually requires staining unless a visible label is 
incorporated into the PCR product. Ethidium bromide is commonly used to stain 
gels containing DNA. Ethidium bromide intercalates with double stranded or 
single stranded DNA and fluoresces orange when exposed to UV light. The 
results of ethidium bromide staining can be seen in Figure 27. However, ethidium 
bromide is thought to be mutagenic because it inserts itself between two strands 
of DNA and is considered a hazardous material. There are other non-mutagenic 
stains that have become available recently, but in this research staining was not 
used before the DNA sample was removed from the gel. Using the fluorescent 
label in the PCR products, the aptamer was identified and excised easily using a 
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UV light. The gel was stained afterwards with ethidium bromide to ensure that the 
PCR product had indeed been double stranded and of the correct size and that 
the remaining, longer strand was still in the gel. If the aptamer had been stained 
with ethidium bromide before its excision from the gel, contamination of 
equipment and reagents would have resulted.
! Gel electrophoresis is a handy tool in isolating DNA. DNA can be removed 
and recovered from an agarose, polyacrylamide, and denaturing polyacrylamide 
gel without altering the DNA in any way. A solution to solubilize the gel 
surrounding the DNA and a method for purification are all that are required to do 
so. Many biological supply companies sell kits for such a purpose.
4.4 Molecular cloning. Molecular cloning is the best way to reproduce large 
quantities of a chosen DNA sequence. Escherichia coli is a commonly used 
bacteria for molecular cloning. The bacteria contains a plasmid which is a small, 
circular DNA molecule that self-replicates. The plasmid DNA is not related to the 
bacterial chromosome which is located elsewhere in the bacteria. The plasmid 
can be altered and made to produce copies of a chosen DNA sequence.
! The selected DNA sequence is inserted into the plasmid DNA forming a 
recombinant DNA plasmid. This plasmid is then inserted into a bacterium. As the 
bacterium clones itself, the chosen DNA sequence is cloned along with it 
producing a colony of bacteria containing the chosen DNA insert. This plasmid 
DNA can then be extracted from the bacteria colony by lysing the bacteria and 
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collecting and purifying the cell remnants. If the DNA sequence that is used in the 
insert is responsible for protein expression, the protein is also produced in the 
cloned bacteria colony and can be extracted just as the sequence is. Many 
biological suppliers produce kits intended for such purposes.
4.5 Modified SELEX procedure. A random ssDNA library containing 
approximately 460 sequences was acquired from Integrated DNA Technologies 
(Coralville, IA). Each random sequence consisted of a central section composed 
of 60 nucleotides, which were random, flanked on both sides by a known string of 
18 nucleotides. Knowing this string was key as this is where the primers used 
later on in PCR would have to bind to duplicate the binding sequences. The basic 
design of the library sequences and PCR primers is seen in Figure 29.
Fig 29.  Sequence diagrams of the aptamer libraries and primer used in PCR. The library 
contains 460 different sequences flanked on both sides by known sequences of 18 nucleotides. 
The modified primer 1 contains a FITC label making it easy to find with a UV source. Modified 
primer 2 contains a poly A label of 18 adenosine nucleotides, making its PCR products longer 
than the products created by modified primer 1.
!
! 10 μg of CA-125 was spotted and dried onto a nitrocellulose membrane in 
ten separate spots. After the spots dried, the membrane was placed in a conical 
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tube with a solution containing approximately 2-3 nmol of a random ssDNA 
library in binding buffer (100 mM NaCl, 20 mM Tris pH 7.6, 2 mM MgCl2, 5 mM 
KCl, 1 mM CaCl2, 0.02% Tween 20). Before exposure to the membrane, the 
library was heated at 90°C for ten minutes to separate any strands that were 
bound together then cooled on ice for five minutes.
! Binding took place for two hours. The membrane was then thoroughly 
washed in binding buffer to remove unbound aptamer sequences. Squares from 
the membrane containing CA-125 and bound aptamers were excised and placed 
in an elution buffer (40 mM Tris pH 8.0, 10 mM EDTA, 3.5 M urea, 0.02% Tween 
20) at 80°C for seven minutes with shaking. This was repeated twice with the 
aptamers being removed and pooled each time. 
! After pooling, the aptamers were purified using the QIAquick gel extraction 
kit from Qiagen (Valencia, CA). This purified, concentrated ssDNA was then used 
as the template in a PCR reaction that followed. The PCR reactions contained 
the following: 71.2 μL of sterile DI water, 10 μL of 10 mM PCR reaction buffer 
from Invitrogen (Carlsbad, CA), 2 μL of 10 mM dNTPs, 5 μL each of 100 μM 
primers, 2 ng of template, 3.8 μL of 50 mM MgCl2, and 5 U of Taq polymerase 
also from Invitrogen.
! The PCR conditions were as follows: 94°C for three minutes for a hot 
start, followed by 30 cycles of 94°C for one minute, 51°C for one minute, and 
72°C for one minute. An extension time of ten minutes at 72°C was carried out 
after the last cycle followed by cooling to 4°C.
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! It was necessary to determine the optimal conditions for the PCR cycle. 
The hot start temperature was determined by Invitrogen, the Taq polymerase 
manufacturer. An elongation temperature of 72˚C is fairly standard and was 
never altered during experimentation. The annealing temperature was the 
temperature that needed to be experimentally determined. It is dependent on the 
primer composition and length and thus tends to be unique to each reaction. A 
range of temperatures in one degree increments ranging from 50˚C to 60˚C was 
used with 51˚C creating the most efficient PCR reaction as judged by the relative 
brightness of the PCR products in a 4% LMP agarose gel.
! To make the PCR process as efficient and specific as possible the enzyme 
used to amplify the DNA was optimized. Along with the Taq polymerase from 
Invitrogen, HOT FIREPol® DNA polymerase (Solis Biodyne, Tartu, Estonia) and a 
high fidelity DNA polymerase from New England Biolabs (Ipswich, MA). The 
same quantity of all three enzymes, 5 U, was used in a PCR. To compare the 
enzymatic production, the PCR products were run through a denaturing 
polyacrylamide gel and the gel was then stained with ethidium bromide to 
visualize the products. The results, seen in Figure 30 indicated that the enzyme 
from Solis Biodyne produced a nonspecific band in the PCR product and that 
while the polymerase from Invitrogen and New England Biolabs both produced 
about the same amount of PCR product, the polymerase from Invitrogen would 
be more convenient to use due to it creating the mechanism required from 
molecular cloning during the amplification process, described in section 4.7 , 
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whereas the New England Biolab enzyme did not and the PCR products would 
have to be modified before successful molecule cloning could occur. 
 Fig 30. Results of PCR products created using different enzymes from different manufacturers 
visualized by ethidium bromide staining in a 10% polyacrylamide, 7M urea denaturing gel. The 
enzyme from Solis Biodyne creates a nonspecific product. The enzymes from New England 
Biolabs and Invitrogen created PCR products with the same efficiency, but the enzyme from 
Invitrogen was chosen because it created PCR products that did not require further modification 
before molecular cloning.
! Following amplification the dsDNA products had to be separated so that 
the aptamers that bound to CA-125 could be pooled and used in the next 
selection round. A 10% polyacrylamide gel containing 7 M urea was used to 
separate the PCR products. 10 μL of PCR products were combined with 10 μL of 
loading buffer (8 M urea, 20 mM Tris, 20 mM EDTA) and heated at 95°C for five 
79
minutes to separate the products. This solution was then loaded into the gel and 
run at 132 mV for 1 hour. The suggested voltage for gel electrophoresis is 8V/cm 
based on the length of the gel. The gel was then placed under a UV 
transilluminator where the binding band was easily visible due to the FITC label 
on one of the primers. These bands containing the binding sequences were 
excised from the gel.
! The make-up of the denaturing polyacrylamide gel was experimented with. 
Clear separation of the DNA strands was key and that required the gel to run 
cleanly, leaving sharp bands that were truly separated. Gel combinations 
experimented with include a 10% polyacrylamide gel containing 7 M urea (Fisher 
Scientific, Fair Lawn, NJ) and 20% formamide (Fisher Scientific), a 10% 
polyacrylamide gel containing 10 M urea, and a 10% polyacrylamide gel 
containing no denaturing reagent. The sample loading buffer was also 
experimented with.Variations included 10 M urea, 10 M urea with 20% 
formamide, and 8 M urea with 20% formamide. Figure 31 represents the results 
of these variations.
! It was determined that a denaturing polyacrylamide gel composed of 10% 
acrylamide/bis solution, 29:1 from Bio-Rad (Hercules, CA), 7 M urea, 1X TBE, 
and a 10:1 ratio of ammonium persulfate to TEMED (both purchased from Bio-
Rad) formed a gel that was effective in separating the double stranded PCR 
product. The best sample loading buffer was 8 M urea, 20 mM Tris (Invitrogen), 
and 20 mM EDTA (Invitrogen).
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Fig 31. Gel composition determination. a, b) Denaturing polyacrylamide gel containing 10% 
polyacrylamide, 20% formamide, and 7M urea. Neither the a) PCR products nor the b) base pair 
ladders run smoothly. c) Denaturing polyacrylamide gel containing 10% polyacrylamide and 10M 
urea. The high urea concentration created deposits of urea at the bottom of the wells preventing 
the PCR products from entering the gel. d) Denaturing polyacrylamide gel containing 8% 
polyacrylamide and 7M urea. The low concentration of polyacrylamide fails to create enough 
pores for the PCR products to travel through. As a result, the smaller PCR products move through 
the gel more quickly than the dye and the larger PCR product is not visible. The larger products 
are located within the dark spots which is the dye.
!
! To extract the DNA from the polyacrylamide gel the QIAEX II kit was 
purchased from Qiagen. The excised bands were placed in centrifuge tubes, 
crushed using a pipette tip, and then placed in 200 μL of diffusion buffer (300 mM 
magnesium acetate pH 7.8, 2 mM NA-EDTA) at 50°C for 30 minutes. !
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! After 30 minutes, the centrifuge tubes were spun down at 8000 RPM for 
one minute. The supernatant was collected and filtered using a 1 mL syringe and 
a 0.22 μm filter. A volume of 6X the volume of filtered supernatant of Buffer QXI, 
which was provided with the kit, was added to the supernatant. An additional 10 
μL volume of QIAEX II silicon beads were added. The solution was vortex mixed 
every two minutes for ten minutes to give the beads time to bind to the aptamers.
! After incubation the tubes were centrifuged and the supernatant removed. 
The beads, now bound with the aptamers, were washed twice with 500 μL of 
Buffer PE, also provided with the kit. The beads dried for ten minutes until the 
beads had just begun to turn white. 20 μL of 10 mM Tris, pH 8.0, was added to 
the beads and the pellet resuspended by vortex mixing. After five minutes the 
tubes were again centrifuged and the supernatant, containing the aptamers, was 
collected. This elution step was repeated twice to improve the yield.
! These collected aptamers were then used in the next round of the SELEX 
procedure. Initially, in the second round, the entire pool of aptamers collected 
from the first SELEX round was used. After that, between 35-70 ng of collected 
aptamers were used in each subsequent SELEX round. Ten rounds of positive 
selection following this procedure were carried out.
4.6 Counter SELEX procedure. To create a more specific aptamer pool, six 
counter selection rounds followed the first ten rounds of positive selection. The 
counter selection rounds were carried out against bovine serum albumin (BSA), a 
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common serum protein, and CEA. In all of these counter selection rounds the 
protein was spot dried onto the membrane just as the CA-125 had been in the 
positive selection rounds. However, for these rounds, any sequences bound to 
the membrane were removed from the selective aptamer pool. The remaining 
selective sequences were purified, used in a PCR, and separated using a 
denaturing polyacrylamide gel as outlined above.
4.7 Molecular cloning of aptamers. After the tenth round of positive selection 
and sixth round of counter selection, a PCR was used to create a pool of suitable 
aptamers for cloning. The PCR used unmodified versions of the primers used 
during the modified SELEX procedure. These primers did not contain FITC or 
poly A labels.
! Using a TOPO TA Cloning Kit purchased from Invitrogen the aptamer pool 
was successfully cloned into E. coli bacteria. This particular kit was chosen 
based on its compatibility with the enzyme, Taq polymerase, used in the PCR 
process. Taq polymerase indiscriminately adds a single deoxyadenosine, 
represented by the letter A in DNA and RNA diagrams, to the 3ʼ ends of PCR 
products as seen in Figure 32. The vector used with the TOPO cloning kit 
contains a single overhanging deoxythymidine, represented by the letter T, on the 
3ʼ end. The binding between the deoxyadenosine and deoxythymidine enabled 
the aptamer to ligate with the vector and thus be inserted into the bacteria. Figure 
33 contains a map of the pCR®4-TOPO® plasmid used in this kit. There are a 
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total of 3956 nucleotides not including the PCR products being cloned. The PCR 
product is inserted into the plasmid at the 294th nucleotide.
Fig 32. Cloning of PCR products. The topoisomerase adds a single adenosine nucleotide to the 3ʼ  
end of the PCR products. This overhang is the mechanism for the PCR productʼs insertion into 
the plasmid DNA.
Fig 33. Map of the pCR®4-TOPO®. The cloning site is located at bases 294-295.
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! The cloning solution was then prepared by combining 4 μL of the PCR 
products, 1 μL of a salt solution that increased the number of transformants by 
2-3 fold, and 1 μL of the TOPO vector. This solution was gently mixed and 
incubated at room temperature for 30 minutes.
! A vial of bacterial cells was thawed on ice and 2μL of the cloning solution 
was added to it and gently mixed. The cells and solution were then incubated on 
ice for 30 minutes. The cells were then heat shocked at 42˚C for seconds and put 
on ice. 250 μL of S.O.C. medium was added to the vial and it was placed in a 
37˚C incubator with horizontal shaking for one hour.
! Agar plates prewarmed at 37˚C for 30 minutes were spread with 25 μL of 
the bacteria using sterilized glass beads. The plates were then incubated 
overnight at 37˚C. The following day 50 colonies were picked and cultured 
overnight in 3 mL of LB medium at 37˚C to allow for further growth.
! The plasmid DNA was extracted and purified using the Plasmid Miniprep 
Kit purchased from Invitrogen. The bacteria from the 50 colonies was pelleted 
and all medium removed. The cells were resuspended in 250 μL of a buffer 
containing RNase A to remove the RNA from the samples. Lysis of the cells 
followed with the addition of 250 μL of a lysing buffer. The cells were incubated in 
this buffer for five minutes at room temperature.
! Immediate mixing with 350 μL of a precipitation buffer took place. The 
samples were then spun down at 12000 RPM for ten minutes to separate the 
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lysate from the lysis debris. The supernatant was extracted and loaded into a 
purification column. The column was placed on a vacuum manifold and the 
vacuum was applied. The column was washed with two different wash buffers 
containing ethanol. The column was placed inside a microcentrifuge tube and 
spun at 12000 RPM for one minute to remove any remaining wash buffer. The 
liquid recovered in the microcentrifuge tube was discarded and the column 
placed inside a new microcentrifuge tube.
! To elute the DNA from the colony, 75 μL of TE buffer (10 mM Tris, 1 mM 
EDTA) preheated to 75˚C was added to the center of the column and incubated 
at room temperature for one minute. The column was then centrifuged at 12000 
RPM for two minutes. The liquid in the bottom of the centrifuge tube contained 
the purified plasmid DNA which was collected for all 50 colonies.
4.8 Return to the modified SELEX procedure. After analyzing the aptamer 
sequences contained in the 50 colonies, explained in further detail in chapter 5, it 
was evident that the aptamer pool must be further refined before a suitable 
aptamer could be identified. Another 18 modified positive SELEX rounds were 
carried out. An altered version of the original binding buffer, called binding buffer 
II and containing 150 mM NaCl, 2 0mM Tris pH 7.6, 2 mM MgCl2, 5 mM KCl, 1 
mM CaCl2, 0.02% Tween 20, was used to carry out nine rounds of positive 
selection. The idea behind altering the buffer by increasing the NaCl 
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concentration from 100 mM to 150 mM was to increase the stringency of the 
binding conditions, resulting in a more specific aptamer pool.
! After nine rounds using binding buffer II, the buffer was again altered by 
increasing the NaCl concentration, 150 mM to 250 mM, and the Tween 20 
percent,0.02% to 0.05%.  Nine rounds of positive selection using this binding 
buffer, called binding buffer III, were carried out. The result of all of these 
modified SELEX rounds was a refined aptamer pool that was suitable for 
evaluation using molecular cloning techniques and sequence analysis.
4.9 Aptamer insert selection directly from molecular cloning. After the final 
18 rounds of positive selection for CA-125 and the six counter selection rounds 
against BSA and CEA, the aptamer pool was reevaluated.!
! Using the pool of aptamers, a PCR was run using the unmodified versions 
of the primers. Molecular cloning using this PCR product was carried out as 
described in section 4.7 to the point of spreading the colonies using the glass 
beads and letting them grow overnight in a 37˚C incubator. Before the cloning the 
size of the PCR products to be cloned was verified using a 4% LMP agarose gel. 
Figure 34 estimates the size of most of the PCR products to be between 75 and 
96 bp in a 4% LMP agarose gel.
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 Fig 34. Verification of PCR insert size. A 4% LMP agarose gel containing two DNA ladders and 
the PCR products used for molecular cloning. The gel is stained with ethidium bromide to 
visualize the contents. The blue box identifies the 100 bp rung in the DNA ladders. The red box 
contains the PCR products whose length, 96 bp, falls just short of the 100 bp mark. This served 
as an adequate benchmark to ascertain that the PCR products were appropriate for cloning.
! The following morning 25 colonies were picked and placed in 2 5μL of 
sterile, DNase free water. At the same time that the colonies were picked an agar 
plate, pre-warmed to 37˚C, was gridded, labeled, and touched with a selected 
colony so that the colonies could be regrown and preserved for future use. The 
remaining unpicked colonies were sealed and placed at 4˚C until further use.
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! The 25 selected colonies were boiled for ten minutes. The cell debris was 
spun down at 13000 RPM for one minute and the supernatant, containing the 
plasmid DNA was collected. 
! A PCR was run using the plasmid DNA as the template and using the 
modified primers to amplify the plasmid insert. Because the primers bind to the 
priming site of the aptamer insert, only the aptamer was copied during this PCR. 
The PCR conditions outlined in the SELEX Procedure, section 4.5, chapter 
proved to be optimal for the plasmid PCR and they were followed exactly.
! Just as in the SELEX procedure, section 4.5, the PCR products were run 
through a 10% denaturing polyacrylamide gel and the binding strands, 
identifiable by the FITC label, were excised from the gel and purified using the 
Qiagen Qiaex II kit. 
! A total of 50 colonies were chosen to have their aptamer insert extracted 
and collected following this procedure. By doing this it was possible to analyze 
the affinity and specificity for CA-125 that each aptamer exhibited and to 
determine the best aptamers to have sequenced and incorporated for use in a 
biosensor.
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Chapter 5:
Aptamer screening through sequence analysis and ELISA development
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5.1 Analysis of cloned sequences. The purified plasmid DNA was sequenced 
by the MMI DNA Analysis Core Facility located at Oregon Health & Science 
University. The returned sequences went through a screening process to 
determine the accuracy and quality of the sequencing data, whether there were 
any repeated sequences that were cloned, what the most common DNA motifs 
present in the sequences were, and what similarities existed in the secondary 
structure of the cloned sequences.
! The sequencing data was verified using 4Peaks from Mekentosj. This 
software loads the raw sequence data and by creating peaks for every 
recognized nucleotide allows visual inspection of the quality and accuracy of the 
sequence that is identified. If the peaks are narrow, pronounced, and do not 
overlap, then the nucleotide that has been identified at that particular location in 
the sequence is correct. Figure 35 compares data representing poor and 
accurate sequence identification as analyzed by 4peaks. If the peaks are broad 
with small amplitudes and overlap with neighboring peaks, there may exist a 
misidentification of the nucleotide at that position in the sequence. 
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 Fig 35. Analysis of sequencing data using 4peaks software. It is important to analyze the quality 
and accuracy of the sequencing data for aptamer analysis. Without proper identification of the 
aptamer sequence it is impossible to further analyze the structure of the aptamer. a) Poorly 
identified sequencing data. Broad, overlapping peaks signal possible misidentification of the 
nucleotide at that position in the sequence. b) Accurate identification of the sequence. Individual 
peaks for each nucleotide are present at each position in the sequence with minimum noise. 
! The 50 sequences initially chosen from the first cloning attempt were 
examined using 4Peaks with 47 of those containing highly accurate sequence 
data. The 4Peaks software also enables the user to search out a particular string 
of nucleotides. The cloned sequences, 96 bp, were able to be identified from the 
entirety of the plasmid DNA, which was 3,956 bp, based on the primer 
sequences. Both the individual binding aptamers and the reversed 
complimentary strands to the binding aptamers were discovered within the 
plasmid DNA by searching for the primer sequences. The sequences containing 
the primer whose modified version contained the FITC label were the binding 
sequences. The sequences containing the primer whose modified version 
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contained the poly A label was the reverse compliment sequence of the binding 
sequence. These sequences were identified, taken the reverse compliment of if 
necessary, and translated into a FastA format.
! Once in this format, the sequences were analyzed using ClustalX, a DNA 
alignment program from University College Dublin. The sequences were 
compared to each other using the program and several alignments of the 
sequences were attempted without any success. It was found that two of the 
sequences were duplicates of each other.
! Lacking an overall alignment, motifs were sought using DiLiMoT. DiLiMoT 
is a web based server that searches files for short repeating sequences called 
linear motifs [54]. These motifs range from 3-8 nucleotides long. Common motifs 
indicate a commonality in the sequence structure that could be responsible for 
the binding between the sequence and the target. After analyzing the 47 
sequences with DiLiMoT, sequences containing the one or more of the ten most 
common motifs were collected for further analysis. From these sequences the 
ones that contained three or more of these ten most common motifs were 
collected for structural analysis. The number of sequences that remained for 
more analysis at this point was nine.
! The structure of the aptamer is responsible for its ability to bind to a target 
protein so it was to be expected that there would be similarities in the secondary 
structure of the aptamers that contained the most common motifs. mfold is a web 
based server that determines the possible secondary structures of DNA 
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sequences by computing the minimum free energy [55]. The number of 
secondary structures ranged between 1 and 7 possible structures for each 
sequence. Each of these possible structures was compared to all other possible 
structures for the nine remaining sequences. Figure 36 contains examples of the 
structures of the selected aptamers derived from mfold.
! The possible structures were made up of loop and stem structures. Each 
possible structure was first compared to the other possible structures for the 
same sequences to find any conserved regions that were constant in every 
structure. These conserved structures were compared to the other possible 
structures for the other sequences. 
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  Fig 36. Examples of the secondary structures of the aptamers obtained from mfold. These are 
four possible structures for four different aptamers. Secondary structures like these were 
investigated for any similarities that might be present among the sequences to find the 
mechanism responsible for binding between the aptamers and CA-125. 
! The five sequences that contained the most structural similarities with the 
other sequences were selected for synthesis. The synthesis was done by IDT. 
The entire 96 bp aptamer, including the primer regions, was synthesized, HPLC 
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purified, and biotinylated. Further analysis through ELISA, described in section 
5.4, was used to determine the aptamer most suitable to binding with CA-125.
5.2 ELISA background. The enzyme-linked immunosorbent assay, ELISA, is a 
commonly used assay to detect a target in a liquid sample. Generally, a binding 
reagent, such as an antigen, is coated onto the bottom of the wells of a high 
binding polystyrene 96-well plate. A liquid sample, possibly containing the ligand 
for the binding reagent, such as an antibody, is incubated in the wells and given 
ample time to bind to the binding reagent. 
! The binding complex is then built up by the addition of other ligands to the 
well with one of the ligands containing an enzyme capable of inducing a color 
change when combined with a particular substrate. The color change is directly 
correlated to the amount of material bound in the well. 
! Washing steps, usually with a nonreactive buffer containing a small 
percentage of a mild detergent, occur after every ligand additive step to remove 
any unbound ligating reagents. Nonspecific sites of the well without the initial 
binding reagent bound to them must also be blocked. The wells are high binding 
and it is possible for a ligand not specific to the original binding reagent to bind to 
the well and create a false signal. ELISAs have been developed to detect a large 
number of targets including antigens, antibodies, drugs, allergens, toxins, and 
hormones. 
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5.3 ELISA procedure for aptamer pool analysis. As the aptamer pool was 
developed and refined it was necessary to evaluate the progression of the poolʼs 
selectivity and affinity for the target protein, CA-125. ELISAs were developed for 
this express purpose. Figure 37 is a composite drawing showing the components 
of the ELISA developed for testing the aptamer pools.
! The bottom of a high binding 96-well plate was coated with 50 μL of 2 μg/
mL solution of CA-125 in carbonate/bicarbonate buffer and incubated onto the 
plate overnight at room temperature. Several washing steps in PBST and PBS 
removed any unbound CA-125.The nonspecific binding sites were blocked with a 
5% solution of skim milk in the binding buffer that was used to bind the aptamers 
to the CA-125. A volume of 350 μL of the blocking solution was placed in each 
well of the plate so that the well was filled and all sites effectively blocked. This 
blocking solution was incubated in the plate for two hours at room temperature. 
Washing with PBST and PBS followed to remove the blocking solution.
! The aptamers, containing an FITC label and ranging in concentration from 
10nM to 0.3125 nM in binding buffer depending on the exact ELISA being carried 
out, were placed in the bottom well at a volume of 50 μL. Binding between the 
aptamers and CA-125 took place overnight at room temperature. Before being 
placed in the well, the aptamers were heated at 95˚C for five minutes and 
immediately placed on ice to ensure the aptamers were separated. The plate 
was washed with PBST and PBS to remove any unbound aptamers. 
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! The well was next filled with 50 μL of a 1:1000 solution of an antiFITC 
mouse antibody in 0.1% skim milk in binding buffer. The antiFITC was purchased 
from Sigma Aldrich and the 1:1000 solution was half of the manufacturers 
suggested dilution as it was unclear if the suggested amount of 5 μg/mL of FITC 
was present in the well. This solution was incubated in the well for two hours at 
room temperature. The plate was washed with PBST and PBS to remove the 
excess antibody. 
! The final component of this sandwich ELISA was the addition of 50 μL of 
1:5000 monoclonal anti-mouse IgG conjugated with horseradish peroxidase 
(HRP). This antibody was purchased from Millipore (Temecula, CA) and prepared 
at the manufacturerʼs suggested dilution. Again, this secondary antibody solution 
was made in 0.1% skim milk in binding buffer. It incubated in the well plate for 
one hour at room temperature.
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 Fig 37. Diagram of the ELISA for testing the aptamer pools. CA-125 is coated on the bottom of 
the well. FITC-labeled aptamers, represented by angular black lines, bind to the CA-125. An 
antiFITC antibody binds to the FITC and a protein IgG conjugated with HRP binds to the 
antiFITC. A TMB substrate is added to the wells, reacts with the HRP, and produces a readable 
signal. Image is not to scale.
! Excessive washing with PBST and PBS followed this incubation as it was 
imperative to remove any unbound HRP, thus minimizing the potential of a false 
signal. The wells were then filled with 50 μL of TMB substrate solution, 
purchased from Sigma Aldrich, which induced a color change over a period of 30 
minutes at room temperature. Finally, 50 μL of the stop reagent, purchased in 
conjunction with the TMB substrate, was added quickly to the wells to stop the 
enzymatic reaction responsible for the color change. The absorbance of each 
well was measured at a wavelength of 450 nm using an ELISA plate reader 
(BioTek, EL 800). The absorbance values were blank adjusted and analyzed 
using Open Office Spreadsheet. 
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5.4 ELISA procedure for synthesized aptamers. Once the five selected 
aptamers had been synthesized, HPLC purified, and biotinylated, and ELISA was 
developed to determine which aptamer exhibited the strongest affinity for 
CA-125. Figure 38 is a diagram of the ELISA developed for this purpose.
! The five chosen aptamers had been selected from the aptamer pool that 
had undergone ten positive selection rounds for CA-125, three counter selection 
rounds against bovine serum albumin (BSA), and three counter selection rounds 
against CEA. To determine the effectiveness of the positive and counter selection 
rounds, the wells of the ELISA plate were coated with 50 μL of 2 μg/mL CA-125, 
CEA, and BSA in carbonate/bicarbonate buffer and incubated overnight at room 
temperature. Washing with PBST and PBS followed. The nonspecific binding 
sites were blocked using 350 μL of 5% skim milk in binding buffer for two hours 
at room temperature. The plate was washed with PBST and PBS.
! Each of the five biotinylated aptamers were made at concentrations of 50, 
10, 2, 0.4, 0.08, and 0.016 μg/mL, or a 1/5 series of dilutions, in binding buffer. A 
volume of 50 μL of all six aptamer concentrations was placed in the wells with 
CA-125 absorbed onto them. The three highest aptamer concentrations were 
placed in wells with CEA absorbed onto them and the highest concentration of 
each sequence was placed in the wells containing BSA. The wells containing 
CEA and BSA also received 50 μL of each aptamer concentration.
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! After the aptamers were incubated overnight at room temperature the 
wells were washed with PBST and PBS and 50 μL of a 10 μg/mL streptavidin-
HRP conjugate in 0.1% of skim milk in binding buffer was added to the wells and 
incubated over the course of an hour at room temperature. The wells were 
washed with PBST and PBS and 50 μL of TMB substrate was added to the wells. 
After 30 minutes 50 μL of the stop reagent was added to each well and the 
absorbance of each well on the plate was read at 450 nm by the ELISA plate 
reader. The resulting ELISA showed no binding between the synthesized 
aptamers and CA-125 or CEA. The ELISA was repeated three times and still no 
binding occurred. At this point it was determined that the aptamer pool would 
need to be further refined before a suitable aptamer could be determined. 
101
Fig 38. Overview of ELISA for synthesized aptamers. CA-125 is attached to the bottom of the 
well. The synthesized aptamers, represented by angular black lines, contain a biotin label and 
bind to the CA-125. A streptavidin-HRP conjugate is added to the wells and binds to the biotin. 
Finally a TMB substrate that interacts with the HRP is added to the well producing a color 
change. Image is not to scale.
5.5 ELISA procedure for plasmid DNA inserts. After the aptamer pool was 
refined through an additional 18 rounds of positive selection and molecular 
cloning had been carried out using this refined pool, the aptamers extracted from 
50 colonies were analyzed using ELISA. The purpose of this was to determine 
which of the individual aptamers showed binding to CA-125 and of those which 
ones showed a higher specificity for CA-125 than for CEA before sequencing 
was done. Because all of these aptamers were FITC labeled, the ELISA 
procedure was identical to the ELISA procedure for aptamer pools described in 
section 5.3. All 50 colonies showed binding with CA-125 and 14 of those showed 
considerably more binding with CA-125 than CEA. The results can be reviewed 
in section 6.5. These 14 colonies were sequenced and the results analyzed as 
discussed in section 5.1.
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Chapter 6: 
Results and discussion
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6.1 Results of biosensor for CA-125 detection. A label-free biosensor was 
developed for fast, sensitive detection of CA-125. A sensing layer that 
immobilized monoclonal CA-125 antibodies for capturing CA-125 was developed 
on the IDEs. Varying concentrations of CA-125 were detected by the sensor and 
the resulting change in impedance was measured.
! The change in impedance was derived from the change in impedance 
values when nothing is bound to the sensing layer and when CA-125 has been 
bound to the sensing layer. The results are presented in Figure 39. Impedance 
values were obtained over a range of frequencies between 50 Hz and 1 MHz and 
compared. The most sensitive signal coupled with the least amount of standard 
deviation was obtained at 100 Hz. 
! An increase in impedance values was observed to correspond with 
increasing concentrations of CA-125. The sensor was able to detect CA-125 
down to a concentration of 10 U/mL and up to a concentration of 80 U/mL. 
Distinguishable signals were generated by the sensor when each concentration 
was detected. The sensor is capable of determining whether the amount of 
CA-125 present is within the diseased range. The clinical benchmark for ovarian 
cancer diagnosis when evaluating CA-125 level in serum samples is 35 U/mL 
and above. The signal generated by the sensor at 20 U/mL, which is below the 
threshold, is differentiable from the signal generated by the sensor at 40 U/mL 
which is just above the diagnosis concentration.
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! More testing is needed to be done beyond this narrow range to determine 
the dynamic range of the sensor. Judging by the large change in impedance 
observed for 10 U/mL it appears that the sensor could have the capacity to detect 
lower concentrations. The signal generated by 80 U/mL of CA-125 indicates that 
detection of greater concentrations may be possible. The signal is not saturated 
between 40 and 80 U/mL implying that differentiable signals may be obtained 
beyond 80 U/mL. However, the percent change in impedance is considerably 
lower between 40 and 80 U/mL than between 20 and 40 U/mL so it is feasible 
that the sensor is already working towards the top end of its dynamic range.
 
Fig 39. Detection of CA-125 in spiked buffer. There is a measurable increase in the change in 
impedance with the increasing concentration of CA-125. The biosensor produces a differentiable 
signal between 20 and 40units/mL making it effective in differentiating between diseased and 
non-diseased levels of CA-125 within the clinical range for diagnosis. All data collected at 100 Hz.
105
! This sensor was also used to detect CA-125 in 5% rabbit serum. The 
serum was spiked with CA-125 at various concentrations and the data was 
collected and analyzed in the manner described in the beginning of this section. 
The results are in Figure 40.  In a complex sample the sensor does not appear 
capable of detecting CA-125 below a concentration of 40 U/mL like it does when 
the sample is spiked buffer. A strong signal is obtained at 40 U/mL which is used 
for disease diagnosis. There is little deviation in the signals indicating that the 
sensor is capable of reproducing a reliable signal even in complex samples. 
More data would need to be collected on this sensor before the reliability could 
be properly established. Far fewer of these sensors were tested than the ones for 
spiked buffer samples, which had larger signal deviations.
!  A comprehensive review of this data gave the impression that while this 
sensor was a promising step towards being able to diagnose disease in clinical 
samples, it would be necessary to detect CA-125 below 40 U/mL so that clear 
signals would be generated inside and outside of the diseased concentration 
range. It was this impetus that would result in the development of an aptamer to 
replace the monoclonal CA-125 antibody in the sensing layer.
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Fig 40. CA-125 detection in 5% rabbit serum. 5% rabbit serum was spiked with varying 
concentrations of CA-125. The sensor is unable to detect CA-125 below 40 U/mL. There is little 
deviation in the signals generated and the sensor is capable of generating a signal within the 
diseased range. All data collected at 500 Hz.
! As CA-125 is such an important biomarker for ovarian cancer there has 
been considerable work put into the development of a biosensor for its detection. 
One of the first efforts was a biosensor that used cyclic voltammetry, another 
electrochemical method, to monitor the changes in current over a small voltage 
range when CA-125 was detected by the sensor [56]. This sensor employed a 
sandwich immunoassay to detect CA-125. This sandwich assay included 
magnetic nanoparticles conjugated with an HRP-antiCA-125 complex as the 
sensing probes and thionine-HRP doped silica nanoparticles as recognition 
elements. These particles contained both the enzyme and electron mediator 
labels making the addition of labels into the sensor very convenient. Detection of 
CA-125 concentrations in spiked buffer were between 0.1 and 450 U/mL. 
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! The advantage of this sensor is its large dynamic detection range. 
However, the use of nanoparticles and enzymatic labels increase the cost of the 
device. They also increase the detection time. Two 18-minute incubation steps 
are required before a signal can be generated whereas the label-free sensor 
described above requires only ten minutes for signal generation.
! A sensor very similar to EIS sensor described in this section was recently 
reported. Like the EIS sensor, a SAM was developed on gold electrodes and a 
monoclonal antibody to CA-125 was used to detect concentrations of CA-125 in 
spiked buffer, spiked serum, and whole blood [57]. Cyclic voltammetry and 
differential pulse voltammetry, both electrochemical detection methods, were 
used to obtain the data. The reported detection range was 0.1 to 100 U/mL in 
increasing factors of ten in spiked buffer and spiked serum and from 0.1 to 10 U/
mL in whole blood.
! This sensor has several advantages over the EIS sensor described at the 
beginning of this section. It is capable of detecting a higher and lower 
concentration range and it is capable of detecting CA-125 in whole blood. 
However, the detection time for this sensor is 40 minutes, four times longer than 
the ten minutes required by the EIS sensor. There is also no detection reported 
within the key diagnostic range. The signal change reported between 10 and 100 
U/mL is substantial, but there is no signal change reported for concentrations that 
lie between those concentrations. Any sensor used in a clinical setting would be 
required to differentiate within that concentration gap.
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! The nonfaradaic EIS biosensor described in this section is one of a 
number of promising new biosensors being developed to detect CA-125 that 
could eventually lead to earlier detection of ovarian cancer.
6.2 Results of biosensor for CEA detection. A label-free biosensor was 
developed for the rapid, sensitive detection of CEA in spiked buffer. Nonfaradaic 
EIS data was collected on all eight IDEs for CEA concentrations ranging from 10 
pg/mL to 10 μg/mL. The sensing layer was created using monoclonal CEA 
antibodies. !
!  Impedance measurements were made before CEA was exposed to the 
sensing layer and after CEA had been incubated on the electrodes. The change 
in impedance, which is what is used to quantify the signal generated by the 
sensor in Figure 41, is derived from the change in impedance values when 
nothing is bound to the sensing layer and when CEA has been bound to the 
sensing layer.
! There is an increase in the change in impedance that is linearly correlated 
with the increasing concentration of CEA. The signal appears to saturate at 10 
ng/mL as the change in impedance fails to increase for CEA concentrations 
beyond that. It is assumed that at 10 ng/mL of CEA all available binding sites on 
the sensing layer have been occupied and there is nowhere for the excess CEA 
to bind. As such, 10 ng/mL is considered the top end of the dynamic detection 
range for this sensor. 
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! It would appear that it could be possible for the sensor to detect 
concentrations of CEA lower than 10 pg/mL, but more testing would have to be 
done to ascertain that information. If 10 pg/mL is the lower end of the dynamic 
detection it would still make the sensor capable of very sensitive detection as 10 
pg/mL is three order of magnitude below the concentration used for diagnosis.
 The sensor is effective at detecting CEA within the clinical range of diagnosis 
which is at 10 ng/mL and above. There is a substantial change in the percentage 
change in impedance between 1 and 10 ng/mL. 
Fig 41. Detection of CEA in spiked buffer. There is a direct linear relationship between the 
increase in change in impedance and the increase in the amount of target CEA detected by the 
biosensor. The signal levels out at a concentration of 10ng/mL after which presumably the binding 
sites available on the sensing layer have been saturated. The biosensor if able to discriminate 
between 1 and 10ng/mL, making it effective in differentiating between diseased and non-diseased 
levels of CEA within the clinical range for diagnosis. All data collected at 100 Hz.
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! The sensor described above was also used to detect CEA concentrations 
in 5% rabbit serum. The data was collected and analyzed according to the 
procedure described in this section. The results are in Figure 42. It is difficult to 
determine the sensorʼs capabilities of detecting CEA in a complex sample if there 
are any at all. There is not an increase in the percentage change in impedance 
for every CEA concentration and it is inconsistent in detecting CEA at both low 
and high concentrations. Not as many sensors were developed to detect CEA in 
5% rabbit serum as there were to detect CEA in spiked buffer and it may be that 
the IDEs were defective in some way. More testing would be needed to 
determine if these signals were a consequence of the fabrication process or the 
sensorʼs inability to detect CEA in a complex sample.
Fig 42. CEA detection in 5% rabbit serum. 5% rabbit serum was spiked with CEA at various 
concentrations and detected by the sensor. The results are inconclusive. There is not consistent 
detection at low concentrations or high concentrations. This may be a result of the sensorʼs 
inability to detect CEA in a complex sample or the fabrication process.
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! CEA has recently gained traction as a biomarker for several types of 
cancer and work is being done to incorporate it into a biosensor platform. 
However, there has not been much development in way of developing an 
impedimetric sensor to detect CEA individually making it difficult to compare 
detection achieved with this sensor to detection reported by other groups. As it 
tends to be indicated in a number of diseases it is usually used in a sensor 
designed to detect a large number of targets.
! Recently there was reported an optical biosensor for detecting CEA using 
surface plasmon resonance. A CEA antibody was immobilized onto gold 
electrodes using a SAM [58]. Known concentrations of CEA in spiked buffer 
solution were incubated on the electrodes for the period of one hour and the 
responding signals were measured. With this sensor, the dynamic range of CEA 
detection was reported to be between 3 and 400 ng/mL. 
! Though the SPR sensor has many advantages, such as itʼs high end 
concentration for dynamic detection, it also has many disadvantages when 
compared to the CEA sensor described above. The SPR sensor does not detect 
CEA below a concentration of 3 ng/mL whereas the EIS sensor detects CEA 
down to 10 pg/mL. The time required for the SPR signal is one hour compared to 
ten minutes for the EIS sensor. The development of this nonfaradaic EIS sensor 
is promising step in the ability to detect CEA in patients with ovarian cancer while 
the disease is still in the early stages.
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6.3 Results of biosensor for He4 detection. There were two labeled faradaic 
EIS biosensors developed to detect He4. The initial sensor used a secondary 
antibody to amplify the signal and the second sensor used an enzymatic reaction 
to amplify the signal. The first sensor incorporated a monoclonal He4 antibody 
into the sensing layer on the electrode. Varying concentrations of He4, already 
combined with a secondary He4 antibody held at a constant concentration of 10 
μg/mL to form an immunocomplex, was exposed to the sensor. The Nyquist plots 
were obtained for every concentration and RCT values obtained from them using 
Z-view. These RCT values were then compared to the RCT values obtained from 
the electrodes after the sensing layer was developed on them but before any 
binding with the He4 immunocomplex. These RCT values were compared and a 
resulting measurement of the change in RCT, ΔRCT, was made.
! These ΔRCT values were compared for every concentration of He4 as 
seen in Figure 43. At concentrations below 50 ng/mL He4 is not detected by the 
sensor. He4 concentrations below that resulted in the RCT values dropping. This 
may have been due to the removal of some of the sensing layer during the 
washing procedures. Even when the RCT values did increase, such as for He 
concentrations of 50 and 100 ng/mL, the increase was smaller than the decrease 
in RCT values at lower concentrations. Even for concentrations 50 and 100 ng/
mL the standard error was so high that it could not be stated that there was any 
detection of He4 by the biosensor.
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Fig 43. Detection of He4 using faradaic EIS. An immunocomplex consisting of a varying He4 
concentration bound to a secondary monoclonal antiHe4 antibody, held at a constant 
concentration of 10μg/mL, is detected by the sensor. An RCT value is obtained from each Nyquist 
plot and compared to the RCT value obtained from the sensor before it was exposed to the 
immuncomplex. The resulting change in RCT, ΔRCT, is compared for each immunocomplex 
concentration. The sensor failed to detect the He4 immunocomplex with any consistency or 
reliable change in signal.
! After having no success with the first He4 sensor, a second sensor was 
developed. This sensor relied on the formation of several layers of materials on 
the sensing layer and used faradaic EIS to obtain impedance measurements. A 
sensing layer containing the same monoclonal antibodies as used in the first He4 
biosensor was developed on the electrodes. Varying concentrations of He4, 
already combined with a biotinylated secondary He4 antibody held at a constant 
concentration of 10 μg/mL to form an immunocomplex, was exposed to the 
sensor. Next a streptavidin-HRP conjugate at a concentration of 1 μg/mL was 
exposed to the sensor. Finally, a TMB substrate was exposed to the sensor. 
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! Faradaic EIS data was collected after the incubation of each reagent and 
Nyquist plots were created. RCT values were extrapolated from the Nyquist plots 
and the ΔRCT values obtained. Figure 44 compares these ΔRCT values for the 
development of every layer on the electrodes. The blue data is the ΔRCT values 
when the biotinylated immunocomplex has been detected by the sensing layer. 
The red data are the ΔRCT when the streptavidin-HRP has bound to the 
biotinylated antibody already captured by the sensing layer. Finally, the green 
data are the ΔRCT values when the TMB substrate had reacted with the HRP 
already on the sensing layer.
! The ΔRCT values for the immunocomplex increase linearly with the 
increase in He4 concentration until a concentration of 25 ng/mL. After this, the 
signal seems to have saturated as there may be no more available binding sites 
with the monoclonal antibodies. As a result, the ΔRCT values fall off. The ΔRCT 
values are relatively low for He4 concentrations below 12.5 ng/mL, but they 
increase rapidly between 12.5 and 25 ng/mL. The ΔRCT values increase for every 
He4 concentration when the streptavidin-HRP and TMB labels are added. This is 
particularly true for 1.56 ng/mL, the lowest concentration of He4. At some He4 
concentrations, such as 6.25 ng/ML and 25 ng/ML the addition of the layers did 
not greatly amplify the ΔRCT values. This is to be expected for the He4 
concentration of 25 ng/mL as the signal generated by the immunocomplex alone 
seems to have saturated at that point. !
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! The clinical range for ovarian cancer diagnosis using He4 is still being 
determined. Estimates range from 150 pM to 500 pM which equates to between 
3 and 10 ng/mL. The sensor is able to detect He4 within this range. There are 
clearly differentiable ΔRCT values for 3.125 ng/mL and 12.5 ng/mL. Even without 
the additional streptavidin-HRP and TMB layers, detection of the biotinylated 
immunocomplex generates differentiable signals within this range. These labeling 
layers do greatly amplify the signal at 12.5 ng/mL which is above any cutoff level 
currently under investigation.
! The use of labels is not ideal for any biosensor. They increase the cost of 
the device and the time required for the sensor to generate a signal. They can 
also modify the binding ability of the protein they are attached to which in this 
sensor a secondary antibody, though any effect that the biotin label may have 
had on the secondary antibodyʼs ability to bind to He4 is insignificant enough that 
the antibody can still bind to He4 and the He4 can then be detected by the 
sensing layer. Using the formation of biolayers to enhance the signal presents an 
additional problem. The creation of these layers depends on previous binding 
steps, i.e. He4 must bind to the sensing layer for the streptavidin to bind to the 
biotin and the enzymatic reaction between the TMB substrate and HRP is 
dependent upon the streptavidin-biotin binding. However, the formation of these 
layers does enable detection of He4 down to a concentration of 1.56 ng/mL/
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Fig 44. Labeled detection of He4 in spiked buffer using biotinylated antibodies. Changes in the 
electron transfer resistance, ΔRCT, were extrapolated from Nyquist plots using Zview and 
compared for the formation of every layer on the sensor. Varying concentrations of He4 which 
had already been allowed to bind to a fixed concentration of 10μg/mL of a secondary biotinylated 
antibody were exposed to the sensing layer on the chip. Next, a layer of streptavidin-HRP 
conjugate at a concentration of 1μg/mL was bound to the sensing layer, altering the ΔRCT values. 
Finally, TMB substrate was exposed to the biosensor. During its interaction with HRP, the TMB 
became an insoluble precipitate, further altering the ΔRCT values. 
! There is very little work currently being reported in the development of a 
biosensor for the detection of He4 making it difficult to ascertain how effective 
this sensor is when compared to other sensors. The nearest thing that can be 
found is a talk given at the Trends in Nanotechnology conference in 2008 by 
Darby Kozak [59]. In it, optically encoded nanoparticles are used to detect He4 
and mesothelin in a high-throughput biosensor platform. Beads coupled with 
single-chain variable fragments specific to He4 and mesothelin are used to 
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capture those target proteins. A fluorescent antibody is then used to generate an 
optical signal.
! Using this system, He4 concentrations between 75 and 1100 ng/mL were 
detected in spiked buffer, 20% serum, and whole serum. This data appears to 
never have been published. The range of detection far surpasses the 
concentrations used to determine the presence of disease making it ineffective in 
a clinical situation. The other detraction is that it, like the biosensors described in 
this section, employs labels to generate a signal. Again, this leads to an increase 
in cost and time of detection and possible loss in binding capabilities of the 
labeled molecule.
6.4 Results of multiplexed biosensor for CA-125 and CEA detection. A 
multiplexed sensor was developed to detect CA-125 and CEA simultaneously 
using nonfaradaic EIS. There are a total of eight IDEs located on the biosensor 
chip and they are conveniently separated into two groups of four IDEs. Four of 
the electrodes were functionalized using a monoclonal CA-125 antibody in the 
sensing layer to detect CA-125 and the remaining four electrodes were 
functionalized using a monoclonal CEA antibody to detect CEA.
! As varying concentrations of CA-125 were exposed to the sensor, EIS 
data was collected in the manner described in 3.3. Data was collected on 
electrodes functionalized to detect CA-125 and on the other electrodes that were 
functionalized to detect CEA. By collecting data in this manner it was possible to 
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quantify the nonspecific binding that could occur with a multiplexed sensor that 
was designed to detect two ovarian cancer biomarkers at once while injecting 
only one sample into the device.
! Figure 45 is the multiplexed biosensorʼs detection of CA-125 in spiked 
buffer. The change in impedance was measured at 500 Hz and is derived from 
the change in impedance values when nothing is bound to the sensing layer and 
when CA-125 has been bound to the sensing layer. The data in purple is the 
change in impedance measured from the electrodes specified for the detection of 
CA-125 and the data in orange is the change in impedance measured on the 
electrodes specified for the detection of CEA. It can be seen that the change in 
impedance increases linearly with the increase in CA-125 concentration for both 
the specific and nonspecific electrodes. As with the sensor for detection of 
CA-125 as described in 6.1, the multiplexed sensor generated distinct signals in 
the diseased and nondiseased clinical ranges. Between 20 U/mL and 40 U/mL 
there is a roughly 10% difference in the signal. As 35 U/mL is the cutoff for 
ovarian cancer diagnosis, the sensor is effective in differentiating between the 
two clinical states.
! The nonspecific signal is less than half of the specific signal, but it does 
increase with the increase in CA-125 concentration. At 10 U/mL, there is no 
positive change in impedance measured from the nonspecific electrodes. Even at 
20 U/mL there is only a small change in impedance measured. The signal from 
the specific electrodes never reaches a saturation level implying that the sensor 
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may be capable of detecting larger concentrations of CA-125. However, the 
nonspecific electrodes also do not produce a saturated signal implying that larger 
levels of nonspecific detection may be also be possible. More testing will be 
required to determine the upper boundary on the specific detection range and to 
determine how differentiable that signal is from the nonspecific signal generated 
at this detection boundary.
Fig 45. Multiplexed detection of CA-125. The data in purple is a result of the change in 
impedance that occurred when various concentrations of CA-125 in spiked buffer were detected 
by electrodes functionalized to specifically detect CA-125. The data in purple is the change in 
impedance that was measured when electrodes functionalized for the detection of CEA were 
exposed to various concentrations of CA-125 in spiked buffer. There is nonspecific detection 
measured for concentrations of CA-125 of 20units/mL and higher with the impedance change 
linearly correlated with the concentration of CA-125 present. All data collected at 500 Hz.
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! The multiplexed sensor was also used to detect CEA in spiked buffer. In 
the same way that nonspecific detection was measured for CA-125, when CEA at 
varying concentrations was exposed to the sensor EIS data was collected on 
electrodes functionalized to detect CEA and on the electrodes functionalized to 
detect CA-125. The impedance measurements collected on the electrodes 
specified for the detection of CA-125 generated the nonspecific data.
! Figure 46 compares the change in impedance for specific and nonspecific 
detection of CEA at 500 Hz. There is a linear increase in the change in 
impedance with increasing CEA concentration as shown in the purple data. The 
clinical range for diagnosis is above a concentration of 10 ng/mL and the sensor 
is capable of detecting CEA concentrations within this range. The change in 
impedance doesnʼt change by more than a few percentage points between 10 
and 100 ng/mL implying that the signal is probably close to saturation. The 
nonspecific detection also increases with increasing concentration of CEA. 
Similar to the nonspecific detection of CA-125, the nonspecific signal is roughly 
half of the specific signal making it differentiable from the specific signal.
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Fig 46. Multiplexed detection of CEA in spiked buffer. The data in purple represents the change in 
impedance measured when the electrodes functionalized for the detection of CEA were exposed 
to various concentrations of CEA. The data in orange is the change in impedance measured on 
electrodes that were functionalized for the detection of CA-125, not CEA. This data represents 
the nonspecific detection of CEA by the multiplexed biosensor. All data taken at 500 Hz.
! Figure 47 shows a side by side comparison of the specific and nonspecific 
detection of CA-125 and CEA in spiked buffer. The dark orange bars represent 
the change in impedance resulting from the specific detection of both markers 
and the light orange bars are the change in impedance from the nonspecific 
detection. The change in impedance is greater for CA-125 than it is for CEA 
which is the same trend seen in the sensors developed for individual detection of 
CA-125 and CEA. However, the signal from the nonspecific detection of CEA by 
the CA-125-functionalized electrodes is also larger than the signal from the 
nonspecific detection of CA-125 by the CEA.
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! It seems there is a substantial nonspecific detection with the multiplexed 
sensor. One possible issue may be with the monoclonal antibodies used in the 
sensing layers. Both were obtained using human immunogens from different 
locations; the CEA from human liver and the CA-125 from human ascites fluid. It 
is also possible that the nonspecific binding sites were not completely blocked 
and that the nonspecific antigens bound to these sites. It is also possible that 
there is some cross reactivity that occurs between CA-125 and CEA. Both 
contain heavily glycosylated regions and there are only eight principal sugars in 
human glycoproteins. As such, there are likely some similar sugars between 
CA-125 and CEA which may lead to some overlap in observed binding.
Fig 47. Direct comparison of multiplexed detection in spiked buffer. This is the same data as seen 
in Fig 43 and Fig 44 shown side by side. There is specific and nonspecific detection of CA-125 
and CEA. The change in impedance is larger for the specific detection of CA-125 than for the 
detection of CEA, but the. All data collected at 500 Hz. 
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! The multiplexed sensor was also used to detect CA-125 and CEA in 
spiked 5% rabbit serum. Figure 48 shows the direct comparison of specific and 
nonspecific detection for CA-125 and CEA over a narrow concentration range 
that falls within the range used for clinical diagnosis. Again, a differentiable signal 
was obtained at the diseased level for CA-125 and CEA, 40 U/mL and 10 ng/mL, 
respectively. These signals are much larger than their spiked buffer counterparts. 
The change in impedance for CA-125 at 40 U/mL in buffer is about 19%. In 
spiked serum it increases to 49%. The signal from CEA does not experience as 
much augmentation. It goes from 10% in buffer for 100 ng/mL to 15% in serum 
for the same concentration. This would indicate that something in the serum 
besides CA-125 and CEA are binding to the sensing layer. Again, it may be a 
consequence of the antibodies used in the sensing layer. The specific signaling 
trends of the sensor when detecting the antigens in spiked buffer are also seen in 
the detection of the antigens in spiked 5% serum. For CA-125, there is a large 
change in impedance between 20 and 40 U/mL. For CEA, the change in 
impedance does not vary greatly between 10 and 100 ng/mL.
! The nonspecific detection of CA-125 by the CEA-specified electrodes 
does not experience much of an increase in the spiked serum sample. Even at 
40 U/mL, the nonspecific change in impedance remains below 10%, just as it 
was in the spiked buffer. The nonspecific detection of CEA by the CA-125-
specified electrodes doesnʼt result in a positive change in impedance. Instead the 
impedance value drops when CEA is exposed to the sensing layer on the 
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CA-125 specified electrodes. This may be a result of the shearing off of some 
material on the sensing layer that may occur while the chip is being washed. The 
result is that there is detection of CA-125 and CEA in 5% rabbit serum within the 
clinical range though there is a question regarding what other serum proteins 
may be binding to the sensing layer and generating such a large signal, 
particularly for CA-125. The nonspecific detection signals are minimal when 
compared to the specific detection signals.
! Whether it is used for detection in spiked buffer or serum, it will be 
necessary to explore a fuller range of concentrations to determine the dynamic 
detection limits for this multiplexed biosensor. This is particularly true of the range 
for CA-125 detection as even a 30-50% change in impedance, as seen in the 
data collected in 5% serum, does not saturate the signal. The signal from CEA 
seems to be close to saturation beyond 10 ng/mL and smaller concentrations 
remain to be tested.
!
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Fig 48. Direct comparison of detection of CA-125 and CEA in 5% rabbit serum by the multiplexed 
chip. The dark orange bars represent the change in impedance resulting from the binding of 
CA-125 and CEA to the electrodes specified for their detection. The light orange bars are the 
change in impedance resulting from nonspecific detection of CA-125 and CEA by electrodes not 
specified for their detection. This nonspecific data for CA-125 was collected on the electrodes 
functionalized to detect CEA and the nonspecific data for CEA was collected on electrodes 
functionalized for the detection of CA-125. All data was collected at 500 Hz.
!   Multiplexed sensors have been developed for the simultaneous detection 
of CEA and CA-125. A recently reported sensor used magnetic nanoparticles 
coated with antiCEA and antiCA-125 antibodies to generate a potential shift 
under manipulation by an external magnetic field [60]. This sensor contained five 
electrodes on a microfluidic device and all five were functionalized for the 
detection of a particular antigen. The target antigens besides CEA and CA-125 
were alpha fetoprotein and CA 15-3. There was less than a 10% change in signal 
created by the electrodes when they were exposed to proteins they were not 
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functionalized to detect. CA-125 and CEA were detected at concentrations of 3.5, 
30, and 50 kU/ml and 2, 50, 100, and 180 μg/mL, respectively.
! This nanoparticle based sensor offers several advantages. It is capable of 
detecting numerous targets simultaneously. It is capable of rapid detection; 
signals are generated between 30s and 5 minutes. This is less than half of the 
time required for the EIS sensor described above to generate a signal. The cross 
reactivity is relatively low. It, like the EIS sensor described above, generates 
nonspecific signals below 10%. However, this biomarker panel that is being 
detected is not specific to any one type of cancer but is instead a generic cancer 
panel. This could lead to an increased cost device cost owing to the development 
of the antibody-based sensing layers. The detection range is also unsatisfactory. 
The CA-125 and CEA concentrations detected were well above any used in a 
clinical situation. The multiplexed EIS sensor is a good step towards the ultimate 
development of a biosensor to detect the biomarker fingerprint of ovarian cancer.
6.5 Results of aptamer development through sequence analysis and ELISA 
development. As previously stated, the aptamer selection process occurred in 
two stages. First, ten rounds of positive selection and six rounds of counter 
selection were carried out using the modified SELEX process. An ELISA was 
developed at that point to determine if the aptamer pool was suitable for 
molecular cloning. 
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! Figure 49 contains the results of that ELISA. The aptamer pool exhibits 
binding with CA-125 before and after the counter selection rounds with less 
binding evident at lower concentrations once the counter selection rounds have 
taken place. This implied that some sequences that preferred binding to BSA and 
CEA and had indeed been removed for the aptamer pool. The beginning of a 
concentration dependent curve was developed after the counter selection 
rounds. The binding between the aptamer pool and CEA was probed using 
ELISA. Binding between the pool and CEA both before and after the counter 
selection rounds was quantified. The binding between the pool and CEA did not 
appear to be diminished by the counter selection rounds. However, the signal 
generated by the aptamer pool and CA-125 binding was roughly twice the signal 
generated by the pool binding to CEA making it feasible for the aptamer pool to 
generate distinct signals when detecting the two different proteins. BSA, the 
other counter selective protein exhibited a small amount of binding with the 
aptamer pool both before and after the counter selection rounds implying that the 
aptamer pool did not show a propensity for binding to BSA to begin with.
! Based on the ELISA data it was determined that the aptamer pool was 
suitable for molecular cloning. After cloning, using the process described in 
section 4.7, the plasmid DNA of 50 colonies were sequenced and 50 aptamer 
inserts were identified. Those aptamers were analyzed using the methods 
detailed in Chapter 5. From them five aptamer sequences were chosen for 
synthesis (Table 1). These five sequences were chosen for synthesis based on 
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the quality of the sequencing data, the presence of certain nucleotide motifs, and 
structural similarities. One sequence was present in duplicate within the 50 
sequenced colonies and it was automatically chosen for synthesis based on the 
idea that an aptamer that had high affinity for CA-125 would be present in larger 
numbers as it would have undergone several binding steps and multiple 
amplifications through PCR. In an ELISA exploring the binding capabilities of 
these synthesized sequences, none of these sequences exhibited any binding 
with CA-125.
129
Fig 49. ELISA results from the initial aptamer pool after 16 modified SELEX rounds. The orange 
line is the binding between the aptamer pool and CA-125 after ten positive selection rounds. The 
yellow line is the binding between the aptamer pool and CEA after ten positive selection rounds 
and before any counter selection rounds. The blue line is the binding between the aptamer pool 
and CA-125 after six counter selection rounds on top of the ten positive selection rounds. There is 
less binding between the pool and CA-125 at lower concentrations than there is between the pool 
and CA-125 before any counter selection has taken place indicating that some aptamer 
sequences were indeed removed from the pool during the six counter selection rounds. The 
green line is the binding between the aptamer pool and CEA after the six counter selection 
rounds have taken place. There is no discernible decrease in binding between the aptamer pool 
and CEA after these selection rounds. BSA exhibits little binding with the aptamer pool before or 
after the counter selection rounds.
!
!
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Sequen
ce ID
Aptamer Sequence Number 
of 
Copies
1 TAACCGTTAAGAGGACCACGGAATATATGGGCGAACGCGA
AACCTTGGACAGCTGACGCG
2
2 CTACAGCCAAGTGTGAGATCAAGATCGTAGAGAGTCGGCT
CTGGTCAGAGTATTGGGAGCG
1
3 AAATAGCGCGATTAAATGCAATGAACACTGAGAACTGTCC
GTAGACACGTTCTTACAATG
1
4 CTCAAACTGGGAGAGTGGAACATACAAGACATAACCGCTT
CAGAACTATGACACGTGTTA
1
5 ACGTGAGATCTGGTGCCGGAATACGCACTACTGACCAGAA
TCAAGCAAATACTAGAGTAT
1
Table 1. Summary of the five aptamer sequences chosen for synthesis. These aptamers had 
undergone ten positive selection rounds and six counter selection rounds, molecular cloning, and 
sequencing. Of the 50 aptamers chosen for sequencing, there was only one duplicate sequence.
! The second stage of the aptamer selection process began after none of 
the synthesized aptamer exhibited any binding to CA-125. It was determined that 
the binding conditions may have been too lax to procure an aptamer pool with 
high affinity. To enrich the aptamer pool with highly selective aptamers, 18 
additional positive selection rounds of the modified SELEX procedure were 
carried out. Nine of those rounds were done using Binding Buffer II and the 
remaining nine using Binding Buffer III. Each of these buffers contained a higher 
salt concentration than the binding buffer which preceded them, creating more 
stringent binding conditions for the aptamer pool. After 18 rounds an ELISA was 
used to determine if the additional positive selection rounds had enriched the 
aptamer pool and if the pool was suitable for molecular cloning.
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! Figure 50 contains the results of that ELISA. The binding between the 
aptamer pool and CA-125 increases with the implementation of each successive 
binding buffer. There is more binding between CA-125 and the aptamer pool 
developed after 32 rounds of positive selection than the aptamer pool developed 
after ten rounds of positive selection. Knowing that the aptamer pool now 
exhibited more affinity for CA-125 than it had when the initial molecular cloning 
procedure took place, it was decided that the pool was again suitable for 
molecular cloning.
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Fig 50. ELISA results from 18 additional rounds of modified SELEX. The yellow line is the binding 
between the aptamer pool and CA-125 using the initial binding buffer, Binding Buffer I. The 
orange line is the binding between the aptamer pool and CA-125 after nine additional rounds of 
positive selection using Binding Buffer II which contained a higher NaCl concentration than 
Binding Buffer I. The blue line is the binding between the aptamer pool and CA-125 after the final 
nine rounds of positive selection using Binding Buffer III which contained a higher concentration 
of NaCl and Tween 20 than either Binding Buffers I and II. The data indicates there is more 
binding between the aptamer pool and CA-125 under each successive binding buffer indicating 
that the aptamer pool has become more selective for CA-125.
! After molecular cloning, 50 colonies were chosen and their plasmid DNA 
collected. This plasmid DNA was run through a PCR to amplify the aptamer 
insert. The individual aptamers were then isolated using gel electrophoresis. 
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These 50 aptamers were then used in an ELISA to determine which of the 
aptamers would bind to CA-125 with the highest affinity and neglect to bind to 
CEA.
! All 50 aptamers showed affinity for CA-125 and all 50 exhibited some 
binding with CEA. Table 2 contains a summary of the 14 aptamers that exhibited 
the highest affinity for CA-125 combined with the least affinity for CEA. These 
aptamers were then sequenced. Only aptamers that showed at least 60% more 
reactivity with CA-125 than CEA were selected and sequenced.
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Aptamer from Chosen 
Colony
% More Activity with 
CA-125 than CEA
C4 62.04
C5 74.34
C6 63.59
C7 63.52
C9 65.78
C10 70.20
C15 65.07
C16 70.26
C17 62.55
C23 62.55
C25 77.91
C27 63.26
C30 63.96
C35 62.20
Table 2. Summary of aptamers after further refinement through an additional 18 positive selection 
rounds and molecular cloning. Fifty colonies were chosen after cloning and these colonies were 
boiled down and the plasmid DNA containing the aptamer insert was collected. The aptamer 
inserts were then amplified using PCR and used in an ELISA to determine which colonies had 
contained the aptamer inserts that exhibited the best binding with CA-125 and the ability to bind 
discriminately with CA-125 over CEA. All 50 colonies contained inserts that exhibited binding with 
CA-125 and the colonies listed above showed the strongest preference for binding with CA-125 
over CEA.
! The sequencing data from the 14 colonies was analyzed and it is 
summarized in Table 3. There were multiple copies of three of the sequences. 
Sequence 1 was identified four times and sequences 1 and 2 were each 
identified twice. The size of most of the sequences was unexpected. Whereas 
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the expected size of the aptamer was 96 bp, most of the returned sequences 
were 76 bp long. There were two exceptions; sequences 8 and 9 were both 96 
bp. These short sequences did bind to CA-125 during the ELISA so it can be 
assumed that the 20 nt lost in the modified SELEX process were not key in the 
aptamerʼs binding ability. Figure 34 indicated that there were some PCR products 
that were not 96 bp, but it was a surprise to find so many shortened sequences 
among the few colonies we studied.
! It is possible that these nucleotides were lost during the PCR process. It is 
not uncommon to lose nucleotides through PCR and it is assumed, being as the 
aptamer underwent 32 amplifications through PCR, that it is the culprit. Even just 
the occasional loss of a nucleotide in a single PCR could result in a large number 
of deletions over the course of so many PCRs. Regardless of the source of the 
deletions, the aptamers showed high binding and specificity for CA-125 making 
them suitable aptamers for CA-125.
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Sequence
ID
Aptamer Sequence Number of 
Copies
1 TATCAATTACTTACCCTAGTGGTGTGATGTCGTA
TGGATG
4
2 AATGCCATGATTAGTATTCGTTGTGTGCAAGGT
GTT
2
3 ACCAGCGCTCGCGATAAGTTTTATTTATTTGTCA
TGTTCG
2
4 ACCGGATCATACACATTCTCACATGTAGTCGAC
ATTCTTT
1
5 TGTTAACTTATGGCGATGGGTTAGGGCTTTGTA
ATACTCG
1
6 TAATGGCCACTGGGACACAGCCTTCTCGTGTG
ACTAGGTT
1
7 TATCAATTACTTACCCTAGTGGTGTGATGTCGTG
TGGATG
1
8 ACATAAGGAGGGGCGTCAAGATGGGGGCAAG
GCAGAAGCAGAAAGTACAAAGGTAGGGTA
1
9 CGAGGATCAACAACGAGCAGCCATCCATCGAC
AAGTGCGAAACCAGCGTGCCACAATTGA
1
Table 3. Summary of the sequences of the nine aptamers identified after the second round of 
molecular cloning. After using an ELISA to determine the aptamers that exhibited the best binding 
to CA-125 and the least binding to CEA, the plasmid DNA was sequenced and the aptamer 
inserts identified. Multiple copies of three of the aptamers were found. Specifically, four copies of 
sequence 1 and 2 copies each of sequences 2 and 3 were identified. Multiple copies of the same 
aptamer indicate that the aptamer pool had been successfully enriched and become more 
selective based on the use of buffers creating more stringent binding conditions for the pool.
! Secondary structures were generated for these 14 aptamers using mfold 
and compared to one another. Several conserved structures were identified 
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among the 14 sequences. The results are in Figure 51. The boxed structures 
were found to be repeated in at least one other structure. There were also 
several other conserved structures not represented in Figure 51. Because the 
secondary structure of the aptamer is responsible for its binding ability with the 
target these repeating structures gave valuable information. They proved that the 
pool was enriched and that even though the sequences were different there were 
particular binding mechanisms being selected during the 32 modified SELEX 
rounds. There were two sequences of 96 bp from the 14 that were sequenced. 
They did not have any structures in common. These two sequences did not have 
any common structures with the shortened sequences. 
! Analysis of these structures indicated that the 14 aptamers would all be 
suitable for synthesis and incorporation into a biosensor. There is more work that 
can be done to evaluate the aptamers which are discussed in section 7.3.
!
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Fig 51. Common structures among the 14 selected aptamers. a) Structures repeated in four 
different sequences. b) Structures repeated in three different sequences. c) Structures repeated 
in two different sequences. d) Structures repeated in two different sequences. These repeated 
structures indicated that the aptamer pool had been enriched. The sequences were different but 
contained the same structures.
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Chapter 7:
Conclusions and suggestions for future work
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7.1 Conclusions from CA-125 and CEA biosensor work. Biosensors to 
effectively detect CA-125 and CEA in spiked buffer were developed. The sensor 
to detect CA-125 produced a measurable signal at key concentrations of CA-125. 
When analyzing the overall change in impedance at 500 Hz, the detection of 
CA-125 at a concentration of 10 U/mL produced a 16.13% change in impedance. 
At a CA-125 concentration of 80units/mL, the impedance has increased to 
24.15%, resulting in an 8.02% change in impedance between the highest and 
lowest concentration of CA-125 detected by the biosensor. Most importantly, the 
biosensor was effective in differentiating between the clinical ranges for diseased 
and non-diseased diagnoses. The clinical limit is set at 35 U/mL with a 
concentration of CA-125 in serum higher than that indicating disease. 
! Future work with the CA-125 sensor should include further testing to 
determine the dynamic range of detection by the biosensor. Though not 
necessary in a clinical setting, the ability to detect CA-125 concentrations outside 
of the narrow diagnostic range could be beneficial in a research setting. The 
sensor should also be used to determine its effectiveness in detecting CA-125 in 
whole serum and whole blood samples. 
! Concentrations of CEA were effectively detected by a nonfaradaic EIS 
biosensor at 100 Hz. At 10 pg/mL, the lowest concentration tested, a 3.11% 
change in impedance was measured and at 10 μg/mL, the highest concentration 
detected, an 11.95% change in impedance was detected. The percentage 
change in impedance increases with every concentration up to a concentration of 
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10 ng/mL. At 10 ng/mL, a 12.07% change in impedance was measured and the 
signals from larger concentrations generated signals within 1.5% of that 
maximum. 
! Beyond 10 ng/mL the detection range failed to be dynamic. However, the 
biosensor was effective in differentiating between the clinical ranges for diseased 
and non-diseased diagnoses. The clinical limit is set at 10 ng/mL with a 
concentration of CEA in serum higher than that indicating disease. There is a 9% 
change in impedance between the lowest concentration detected and the 
concentration used to determine if disease is present.
! Future work with the CEA sensor should include testing the sensor over a 
narrower range of concentrations. The concentrations detected by the biosensor 
range from 10 pg/mL to 10 μg/mL increasing each time by an order of magnitude. 
In a research setting it may be necessary to detect CEA at much finer 
concentration increments. The sensor should also be used to determine its 
effectiveness in detecting CEA in whole serum and whole blood samples. 
! Nonfaradaic sensors for CEA and CA-125 in 5% rabbit serum were 
unsatisfactory. The data obtained for the detection of CEA was inconsistent with 
the data obtained for CEA detection in spiked buffer. Though the CA-125 sensor 
was capable of detecting CA-125 in spiked 5% rabbit serum in the clinical range 
for disease diagnosis, low concentrations outside of the diagnosis range were not 
detected as they were in spiked buffer. The shortcomings of these sensors in a 
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complex sample like 5% rabbit serum provided the impetus for developing a 
better sensor through aptamer development.
! The multiplexed sensor was successful in detecting CA-125 and CEA in 
both spiked buffer and 5% rabbit serum. CA-125 was detected between 10 and 
80 U/mL and CEA was detected between 1 and 100 ng/mL. Both were detected 
at the key concentrations used for clinical diagnosis, between 20 and 40 U/mL for 
CA-125 and 1 and 10 ng/mL for CEA. Detection of CA-125 in spiked buffer at a 
concentration of 40 U/mL resulted in a 16.67% change in impedance and 
detection of CEA in spiked buffer at a concentration of 10 ng/mL resulted in a 
9.28% change in impedance. The same concentrations in 5% rabbit serum 
generated a 48.26% and 15.46% change in impedance for CA-125 and CEA, 
respectively. The signals from the spiked serum are much larger than the signals 
from the spiked buffer indicating that some of the material present in the serum 
may be binding to the functionalized electrodes or nonspecific binding sites that 
were not blocked. However, the spiked serum concentrations for both CA-125 
and CEA still generate increasing, differentiable signals for increasing 
concentrations and within the clinical range of diagnosis.
! The nonspecific binding between CEA and the CA-125 specific electrodes 
and CA-125 and the CEA-specific electrodes was quantified. In both cases, the 
nonspecific signal was below a 10% change in impedance even for high 
concentrations of CEA and CA-125. This was true for the data in spiked buffer 
and spiked 5% rabbit serum. 
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! Future work with the multiplexed sensor should include functionalizing 
some of the electrodes to detect He4 to create a sensor to detect all the ovarian 
cancer biomarkers. A larger range of concentrations in diluted serum will be 
necessary to determine the dynamic range. The multiplexed sensor should also 
be tested in whole serum and blood samples.
7.2 Conclusions from and future work with the He4 biosensor. He4 was 
detected using a labeled, faradaic EIS biosensor. The range used for clinical 
diagnosis falls between 3 and 10 ng/mL and He4 was clearly detected both within 
and outside of this range. Differentiable ΔRCT values were obtained from Nyquist 
plots for He4 concentrations between 1.56 and 100 ng/mL in spiked buffer. These 
ΔRCT values were obtained for every labeled layer formed on the electrodes. The 
values obtained from just the first labeled layer generated sensitive, differentiable 
signals. An He4 concentration of 3.125 ng/mL generated a ΔRCT of about 250 Ω 
and an He4 concentration of 12.5 ng/mL generated a ΔRCT of 1500 Ω. Thus, 
differentiable signals within the diagnosis range were generated using just the 
biotinylated antibodies. The subsequent layers of streptavidin-HRP and TMB 
precipitate increased those ΔRCT values.
! Detection below and beyond the clinical range was achieved. With just the 
biotinylated layer an He4 concentration of 1.56 ng/mL generated a ΔRCT value of 
around 125 Ω and an He4 concentration of 25 ng/mL generates a ΔRCT value of 
3250 Ω. A signal is generated at up to 100 ng/mL, but it is significantly smaller 
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than the signal for 25 ng/mL implying that the signal is saturated beyond that 
concentration. All the ΔRCT values mentioned above were amplified with the 
formation of every labeled layer and the same trend of increasing ΔRCT values 
for every concentration of He4 was observed. For the sake of simplicity only the 
values obtained with the biotinylated layer are mentioned.
! Future work will include testing patient serum samples with the sensor to 
determine the presence of He4. These samples are currently being obtained 
from OHSU and testing will begin in the near future.
7.3 Conclusions from developing an aptamer for CA-125 and future 
development of aptamers. Nine possible aptamers for CA-125 have been 
identified after 32 rounds of a modified SELEX procedure. Three of those 
sequences hold particular promise as multiple duplicate copies of them were 
identified in a relatively small pool of molecular clones.
! Further work will include determining the most viable aptamer among the 
nine possible sequences. The goal is to develop a biosensor for CA-125 that 
replaces the monoclonal antibody currently used in the biosensors with one of 
the selected aptamers. Binding assays will be required to determine the aptamer 
with the highest binding affinity for CA-125. The determination of the dissociation 
constant, KD, for each aptamer from the binding assays will play a large role in 
determining the best aptamer. Competitive binding assays will also be needed to 
chose an aptamer. The competitive binding assay should compare the binding 
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ability between the aptamer and CA-125 even when a monoclonal CA-125 
antibody is present and presumably competing with the aptamer for the available 
binding sites. ELISA will also be an important assay tool in determining the most 
suitable aptamer. Through ELISA an aptamer can be selected that will bind to 
CA-125 under possible working conditions for the biosensor, i.e. higher 
temperatures, specialized buffers.
! The combination of these different assays will yield the most suitable 
aptamer and it will be incorporated into a biosensor. This will ideally produce a 
cheaper sensor capable of more sensitive and more specific detection than the 
antibody based biosensor we have developed.
!
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